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Abstract: 
Non-eosinophilic airway inflammation occurs in approximately 50% of 
patients with asthma. It is subdivided into neutrophilic or paucigranulocytic 
inflammation, although the proportion  of each subtype is uncertain 
because of variable cut-off points used to define neutrophilia. This article 
reviews the evidence for non-eosinophilic inflammation being  a target for 
therapy in asthma and assesses clinical trials of licensed drugs, novel small 
molecules and biologics agents in non-eosinophilic inflammation. Current 
symptoms, rate of exacerbations and decline in lung function are generally 
less in non-eosinophilic asthma than eosinophilic asthma. Non-eosinophilic 
inflammation is associated with corticosteroid insensitivity. Neutrophil 
activation in the airways and systemic inflammation is reported in 
neutrophilic asthma. Neutrophilia in asthma may be due to corticosteroids, 
associated chronic pulmonary infection, altered airway microbiome and/or 
delay neutrophil apoptosis. The cause of poorly controlled non-eosinophilic 
asthma may differ between patients and involve several mechanism 
including neutrophilic inflammation, Th2-low or other subtypes of airway 
inflammation and/or corticosteroid insensitivity as well as non-
inflammatory pathways such as airway hyperreactivity and remodelling. 
Smoking cessation in asthmatic smokers and removal from  exposure to 
occupational agents reduces neutrophilic inflammation. Preliminary studies 
of ‘off-label’ use of licensed drugs suggest that macrolides show efficacy in 
non-smokers with non-eosinophilic severe asthma and statins, low-dose 
theophylline and PPARγ agonists may benefit asthmatic smokers with non-
eosinophilic inflammation. Novel small molecules targeting neutrophilic 
inflammation, such as CXCR2 antagonists reduce neutrophils, but do not 
improve clinical outcomes in studies to date. Inhaled PDE4 inhibitors, dual 
PDE3 and PDE4 inhibitors, p38MAPK inhibitors, tyrosine kinase inhibitors 
and PI3kinase inhibitors are under development and these compounds may 
be of benefit in non-eosinophilic inflammation. The results of clinical trials 
of biological agents targeting mediators associated with non-eosinophilic 
inflammation, such as IL-17 and TNF-α are disappointing. Greater 
understanding of the mechanisms of non-eosinophilic inflammation in 
asthma should lead to improved therapies. 
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ABSTRACT 
 
Non-eosinophilic airway inflammation occurs in approximately 50% of patients with asthma. It 
is subdivided into neutrophilic or paucigranulocytic inflammation, although the proportion  of 
each subtype is uncertain because of variable cut-off points used to define neutrophilia. This 
article reviews the evidence for non-eosinophilic inflammation being  a target for therapy in 
asthma and assesses clinical trials of licensed drugs, novel small molecules and biologics agents 
in non-eosinophilic inflammation. Current symptoms, rate of exacerbations and decline in lung 
function are generally less in non-eosinophilic asthma than eosinophilic asthma. Non-
eosinophilic inflammation is associated with corticosteroid insensitivity. Neutrophil activation in 
the airways and systemic inflammation is reported in neutrophilic asthma. Neutrophilia in 
asthma may be due to corticosteroids, associated chronic pulmonary infection, altered airway 
microbiome and/or delay neutrophil apoptosis. The cause of poorly controlled non-eosinophilic 
asthma may differ between patients and involve several mechanism including neutrophilic 
inflammation, Th2-low or other subtypes of airway inflammation and/or corticosteroid 
insensitivity as well as non-inflammatory pathways such as airway hyperreactivity and 
remodelling. Smoking cessation in asthmatic smokers and removal from  exposure to 
occupational agents reduces neutrophilic inflammation. Preliminary studies of ‘off-label’ use of 
licensed drugs suggest that macrolides show efficacy in non-smokers with non-eosinophilic 
severe asthma and statins, low-dose theophylline and PPARγ agonists may benefit asthmatic 
smokers with non-eosinophilic inflammation. Novel small molecules targeting neutrophilic 
inflammation, such as CXCR2 antagonists reduce neutrophils, but do not improve clinical 
outcomes in studies to date. Inhaled PDE4 inhibitors, dual PDE3 and PDE4 inhibitors, p38MAPK 
inhibitors, tyrosine kinase inhibitors and PI3kinase inhibitors are under development and these 
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compounds may be of benefit in non-eosinophilic inflammation. The results of clinical trials of 
biological agents targeting mediators associated with non-eosinophilic inflammation, such as IL-
17 and TNF-α are disappointing. Greater understanding of the mechanisms of non-eosinophilic 
inflammation in asthma should lead to improved therapies. 
 
Word count: 299  
 
Key words: Airway inflammation; asthma; biological agents; biomarkers; cigarette smoking; 
corticosteroid insensitivity; eosinophils; neutrophils; small molecules.  
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INTRODUCTION 
 
Personalised medicine in asthma aims to individualise treatment using non-invasive biomarkers 
that predict a beneficial response and/or that identify individuals who are at risk of adverse 
effects [Agustí et al., 2015]. Several airway inflammatory phenotypes are recognised that help 
identify a therapeutic response to specific treatments in asthma. For example, eosinophilic 
airway inflammation, which is usually identified on the bases of sputum or blood eosinophilia, 
predicts patients with asthma that are likely to obtain a favourable therapeutic response to 
corticosteroids [Pavord et al., 1999, Little et al., 2000, Green et al., 2002, Bacci et al., 2006, 
Berry et al., 2007] and to monoclonal antibodies targeting interleukin (IL)-5 [Pavord et al., 2012, 
Katz et al., 2014, Thomson, 2014].   Type 2 helper T-cell (Th2)-high subtype of asthma is 
associated with increased epithelial expression of interleukin IL-4, IL-5 and IL-13 [Woodruff et 
al., 2009, Arron et al., 2013] and is considered to overlap with eosinophilic airway inflammation 
[Arron et al., 2013]. Evidence from clinical trials suggests that the presence of Type-2 
eosinophilic inflammation predicts a therapeutic response not only to corticosteroids 
[Woodruff et al., 2009], but to monoclonal antibodies targeting specific cytokines such as IL-5 
[Bel et al., 2014, Ortega et al., 2014] and IL-13 [Corren et al., 2011]. Many patients with asthma 
have non-eosinophilic asthma, sometimes associated with neutrophilic inflammation and/or 
have a Th2-low type of inflammation. Compared to type-2 eosinophilic inflammation there are 
relatively few interventions available for non-type 2 inflammatory sub-groups.  This article aims 
to discuss the evidence that non-eosinophilic airway inflammation, with or without neutrophic 
inflammation, is an appropriate target for therapy in asthma and also aims to assess the results 
of recent clinical trials of licensed drugs, novel small molecules and biologics agents in the 
treatment of non-eosinophilic asthma. 
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IS NON-EOSINOPHILIC AIRWAY INFLAMMATION AN APPROPRIATE TARGET FOR THERAPY IN 
ASTHMA? 
 
A number of factors need to be considered when attempting to answer the question of 
whether non-eosinophilic inflammation is an appropriate target for treatment in asthma  
including the criteria used to define neutrophilic and eosinophilic inflammation, the stability of 
non-eosinophil inflammation over time, the prevalence of non-eosinophilic inflammation, the 
strength of evidence for the involvement of non-eosinophilic inflammation in clinical features 
of asthma and the cause(s) of non-eosinophilic airway inflammation.  
 
Definition of eosinophilic and neutrophilic airway inflammation 
 
Non-eosinophilic airway inflammation is a term used to describe a subtype of asthma 
associated with normal numbers of sputum eosinophils. The non-eosinophilic phenotype is 
subdivided into neutrophilic inflammation, when neutrophil numbers are raised above a 
defined cut-off level or paucigranulocytic inflammation, when both eosinophil and neutrophil 
numbers are normal. In addition, some individuals have a mixed type of inflammation, when 
there is sputum neutrophilia and eosinophilia. Cut-off levels used to define sputum eosinophilia 
most commonly used are  >2% [Mcgrath et al., 2012, Hastie et al., 2013], >2%  [Peters et al., 
2014] or  >3% [Schleich et al., 2013, Zhang et al., 2014, Wagener et al., 2015]. A >3% cut-off is 
reported to be the most precise value to identify eosinophilic airway inflammation [Simpson et 
al., 2010]. Sputum eosinophil counts are associated with bronchial tissue eosinophil numbers 
suggesting that they provide a good indicator of airway eosinophilic pathology [Arron et al., 
2014].  The cut-off for a raised sputum neutrophil count is not clearly established with a wide 
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range of values reported in the literature: >40% (Nair, Gaga et al. 2012; Moore, Hastie et al. 
2014), >50% (Chaudhuri, Norris et al. 2014), >61% (Simpson, Milne et al. 2009), >65% (Nair et al 
2015) and >76% (Schleich, Manise et al. 2013). The most appropriate cut-off value that 
identifies individuals in whom neutrophils are activated and contributing to the pathogenic 
processes in asthma is not certain. In addition, sputum neutrophils do not correlate with 
bronchial tissue numbers bringing into doubt their predictive value for identifying neutrophil-
induced airway pathology [Arron et al., 2014].  In addition to the presence of non-eosinophilic 
inflammation, Haldar and Pavord [Haldar et al., 2007] proposed that the criteria for a diagnosis 
of non-eosinophilic asthma should include objective evidence of airflow obstruction or airway 
hyperreactivity, a raised asthma control questionnaire (ACQ) score (>1.5) and the absence of a 
significant smoking history, fixed airflow obstruction or associated bronchiectasis. In the 
current article, the criteria for non-eosinophilic asthma include the presence of non-
eosinophilic inflammation as defined above plus objective evidence of asthma,  but the review 
also includes data from patients with both normal and raised ACQ scores, who have a 
significant smoking history or who have fixed airflow obstruction. 
 
Stability of sputum cell counts 
  
Published data on the long term stability of sputum neutrophil and eosinophil counts is 
conflicting. Some studies report stable sputum cell counts in patients with mild to severe 
asthma follow-up over 6 months [Berry et al., 2007], 12 months [Green et al., 2002], 2 years 
[Jayaram et al., 2006] and 5 years [Simpson et al., 2006, Van Veen et al., 2009].  In contrast, 
sputum inflammatory cell phenotype changed in 48.6% of patients with severe asthma over 
1 year among patients recruited to the BIOmarkers in Severe Chronic AIRway Disease 
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(BIOAIR) study [Kupczyk et al., 2014]. Similar variability in sputum cell counts has been 
reported by others [Hancox et al., 2012]  and in one study a stable inflammatory  phenotype 
was found in only one third of patients [Al-Samri et al., 2010]. Transient sputum eosinophilia 
is reported in up to 40% patients with non-eosinophilic inflammation [Bacci et al., 2012, 
Mcgrath et al., 2012]. The potential for the lack of stability in non-eosinophilic inflammation 
over time needs to be accounted for in intervention studies targeting sputum inflammatory 
cell biomarkers. 
 
Prevalence of non-eosinophilic airway inflammation 
 
The different cut-off values used to define elevated sputum cell counts, particularly sputum 
neutrophils, may explain the variation in prevalence figures for non-eosinophilic 
inflammation between studies. Nevertheless, overall up to 50% of adults and adolescents  
with stable mild to severe asthma, and in some studies higher proportions, have non-
eosinophilic inflammation [Gibson et al., 2001, Green et al., 2002, Simpson et al., 2006, 
Wang et al., 2011, Mcgrath et al., 2012, Schleich et al., 2013, Moore et al., 2014, Brooks et 
al., 2016 ]. For example, a review of sputum cytology data from 995 subjects with mild to 
moderate asthma enrolled in clinical trials undertaken by the Asthma Clinical Research 
Network (ACRN) reported that non-eosinophilic inflammation (sputum eosinophils <2%) was 
present in 64% of patients not taking inhaled corticosteroid and 83% of patients taking 
inhaled corticosteroids. In a sub-group of patients followed up for 6 months, 47% of the 
inhaled corticosteroid  free patients and 72% of those taking inhaled corticosteroids had 
persistent non-eosinophilic inflammation [Mcgrath et al., 2012]. In a cluster analysis 
performed on 423 patients recruited to the Severe Asthma Research Program  (SARP) 
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cohort, four asthma inflammatory sub-phenotypes were identified (sputum eosinophilia 
>2%; sputum neutrophilia >40%) [Moore et al., 2014]. Two groups had mild-to-moderate 
allergic asthma with minimal or eosinophil-predominant sputum inflammation whereas the 
other two sub-phenotypes had moderate-to-severe asthma with neutrophil-predominant or 
mixed granulocytic inflammation [Moore et al., 2014]. A study in a small group of adults 
with stable asthma found 51.7% of subjects had a paucigranulocytic phenotype, 27.6% 
neutrophilic inflammation and 17.2% eosinophilic inflammation [Wang et al., 2011].  
 
Involvement of neutrophilic and non-eosinophilic airway inflammation in asthma  
 
Evidence for the involvement of non-eosinophilic inflammation in asthma is based mainly on 
studies examining the association between sputum inflammatory phenotypes and clinical 
outcomes in asthma including current symptom control, exacerbations, airflow obstruction and 
therapeutic response to corticosteroids. Further evidence is provided by reports of local 
activation of neutrophils and systemic inflammation in neutrophilic asthma. 
 
Current symptom control 
 
The severity of current symptoms is in general similar or slightly lower in non-eosinophilic or 
neutrophilic subgroups of asthma compared to eosinophilic subgroups [Cowan et al., 2010, 
Hastie et al., 2010, Wood et al., 2012, Schleich et al., 2013, Baines et al., 2014, Newby et al., 
2014, Schleich et al., 2014].   
 
Exacerbations 
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Sputum neutrophilia is found in up to 80% of exacerbations in adults with asthma [Turner et al., 
1995, Fahy et al., 1995 , Lamblin et al., 1998, Green et al., 2002, Jayaram et al., 2006, 
Maneechotesuwan et al., 2007, Wang et al., 2011], although the predominant sputum cell type 
can alter during successive exacerbations [D'silva et al., 2007]. Sputum eosinophilia is a better 
predictor of future exacerbations than sputum neutrophilia [Jatakanon et al., 2000, Leuppi et 
al., 2001, Kupczyk et al., 2014, Schleich et al., 2014]. For example, a cluster analysis performed 
on patients recruited to the BIOAIR study identified two clusters with raised sputum eosinophil 
counts that accounted for 83% of subjects who had 2 or more severe exacerbations during 
follow-up  for 1 year [Kupczyk et al., 2014]. One of these clusters had a mixed inflammatory 
profile with raised sputum neutrophils (43% percent of patients). A further cluster had a raised 
neutrophil count and a normal eosinophil count (11% of patients) and a non-eosinophilic 
paucigranulocytic inflammation was found in only 6% of cases. Patients with severe asthma 
associated with eosinophil inflammation have more intubations than non-eosinophilic patients 
[Wenzel et al., 1999]. 
 
Airflow obstruction 
  
Sputum neutrophilia is association with reduced lung function and based on this finding it has 
been speculated that airway neutrophils may contribute to the development of persistent 
airflow obstruction in asthma [Little et al., 2002, Shaw et al., 2007]. Against this hypothesis, a 
recent cluster analysis of lung function decline and sputum eosinophil count performed in 97 
patients with severe asthma identified a non-eosinophilic group in whom the decline in FEV1 
was -14 ml per year compared to an eosinophilic group with highly variable eosinophil counts 
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that had a greater rate of decline in FEV1 of -41 ml per year [Newby et al., 2014]. These findings 
suggest that eosinophilic inflammation, particularly when there is high variability in eosinophil 
count, is a greater risk factor for the development of persistent airflow obstruction than non-
eosinophilic inflammation.  Bronchodilator reversibility and airway hyperresponsiveness are 
similar in eosinophilic and non-eosinophilic asthma [Berry et al., 2007, Mcgrath et al., 2012], 
although one study noted greater airway hyperresponsiveness in persistent or intermittent 
eosinophilic groups [Mcgrath et al., 2012].  
 
Impaired response to inhaled corticosteroids  
 
Non-eosinophilic inflammation is associated with an impaired therapeutic response to 
inhaled corticosteroids [Pavord et al., 1999, Green et al., 2002, Bacci et al., 2006, Berry et 
al., 2007, Thomson et al., 2009, Mcgrath et al., 2012], although the lack of efficacy may not 
be complete. Several clinical studies performed in small numbers of patients with non-
eosinophilic asthma suggest that this group may obtain some benefit from inhaled 
corticosteroids although less than that found in eosinophilic patients [Godon et al., 2002, 
Cowan et al., 2010, Lemière et al., 2011]. Intermittent eosinophilia might be a factor 
accounting for corticosteroid sensitivity in some of these patients [Bacci et al., 2012, 
Mcgrath et al., 2012, Suárez-Cuartín et al., 2015]. 
 
Evidence for neutrophil activation in asthma 
 
There is evidence to suggest that the innate immune system is activated in chronic asthma. 
Firstly, sputum IL-8 and neutrophil elastase concentrations and innate immune receptors 
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TLR2, TLR4 and CD14 as well as pro-inflammatory IL-8 and IL1-β gene expression levels are 
increased in neutrophilic asthma compared to non-neutrophilic asthma [Simpson et al., 
2007, Wood et al., 2012]. Secondly, neutrophil activation, as measured by sputum 
myeloperoxidase (MPO) levels, is positively associated with sputum neutrophil numbers in 
asthma [Little et al., 2002]. Thirdly, specific sputum gene expression signatures are 
reported to discriminate eosinophilic asthma from non-eosinophilic asthma as well as to 
predict a beneficial response to inhaled corticosteroids [Baines et al., 2014]. In this study, 
non-eosinophilc asthma was identified by increased sputum cell expression of IL1β , 
alkaline phosphatase, tissuenonspecific isozyme (ALPL ) and CXCR2, whereas  eosinophilic 
asthma was characterised by increased expression of Charcot-Leydon crystal protein  or 
galectin-10 (CLC), carboxypeptidase A3 (CPA3) and deoxyribonuclease I-like 3 (DNASE1L3). 
The NLRP3 inflammasome is upregulated in neutrophilic asthma and may increase the 
production of IL-1β [Simpson et al., 2014, Kim et al., 2015]. Anti-inflammatory responses 
may be impaired in non-eosinophilic asthma based on reduced sputum galectin-3 
concentrations, which increases uptake of apoptotic neutrophils and reduced IL-1RA/IL-1ß 
ratio, and which might increase pro-inflammatory actions of IL-1ß [Gao et al., 2015]. In 
addition, soluble receptor for advanced glycation end-products (RAGE), which is a pattern-
recognition receptor is deficient in BAL samples in neutrophilic asthma [Sukkar et al., 
2012]. The T-cell granzyme B pathway, which is though to mediate apoptosis of epithelial 
cells, might be defective in non-eosinophilic asthma, based on the finding of a higher ratio 
of the expression of granzyme B to its inhibitor in T cells in this group compared to 
eosinophilic asthma [Simpson et al., 2014]. 
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Systemic inflammation is increased in patients with neutrophilic airway inflammation. The 
proportion of patients with elevated CRP, IL-6 and neutrophil elastase concentrations is higher 
in neutrophilic asthma compared to a non-neutrophic group [Baines et al., 2011, Wood et al., 
2012]. Neutrophilic inflammation is associated with increased α-defensin and neutrophil 
protease gene expression in blood  [Baines et al., 2011]. In non-eosinophilic asthma, blood 
neutrophils released significantly higher levels of IL-8 at rest [Baines et al., 2010].  In a small 
study, gene expression markers of  systemic inflammation were associated with higher BMI, 
greater history of cigarette smoking, lower FVC% predicted, and increased sputum neutrophils 
[Fu et al., 2013]. 
 
Potential inflammatory processes leading to non-eosinophilic airway inflammation 
 
Several inflammatory processes could lead to non-eosinophilic inflammation and airway 
damage in asthma although the exact immunological mechanisms are unclear (Figure 1) 
[Trejo Bittar et al., 2015]. Uncertainty in the clinical relevance of experimental animal 
models of non-eosinophilic inflammation has hampered progress in understanding the 
involvement of neutrophils and non-eosinophilic inflammation in the pathogenesis of 
asthma. Stimuli such as viruses, cigarette smoke and pollutants could induce the release of 
chemoattractants including IL-8 to recruit neutrophils to the airways. In experimental 
asthma models, the release of  IL-17A and IL-17F  from activated Th17 cells stimulates the 
synthesis of neutrophil chemoattractants including CXCL1 and IL-8 from the airway 
epithelium. [Newcomb et al., 2013].  INF-γ may also be involved in the pathogenesis of  
severe asthma associated with neutrophilic and eosinophilic inflammation, possibly in part 
through the release of IFN-γ from Th1 cells [Raundhal et al., 2015 ]. Data from patients with 
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severe asthma and an experimental murine asthma model implicate high INF-γ  immune 
responses and low secretory leukocyte protease inhibitor expression (SLPI) in airway 
epithelial cells with airway hyperresponsiveness [Raundhal et al., 2015 ]. Neutrophils are a 
potential source of oxygen free radicals and enzymes and their ability to activate other 
airway cell types [Futosi et al., 2013]. Neutrophils in asthma are implicated in causing  
mucus gland hyperplasia and hypersecretion, airway hyperreactivity and remodelling as 
well as corticosteroid insensitivity. Interestingly, Th1 and Th17 cells may induce airway 
hyperreactivity and/or remodelling independently of neutrophil activation.   
 
Limited information has been published on the immunopathological characteristics of non-
eosinophilic inflammation in asthma compared with other inflammatory airway phenotypes 
including Th2-low inflammation, Th17-high inflammation or combination of Th2/Th17 profiles. 
Bronchial biopsy studies of patients with non-eosinophilic asthma and with Th2-low 
inflammation report reduced sub-mucosal eosinophil numbers and normal sub-epithelial 
basement membrane thickness in both groups [Wenzel et al., 1999, Berry et al., 2007, 
Woodruff et al., 2009]. In contrast, bronchial eosinophils numbers and sub-epithelial basement 
membrane thickness are both increased in eosinophilic asthma and in Th2-high asthma [Wenzel 
et al., 1999, Berry et al., 2007, Woodruff et al., 2009]. Mast cell numbers are increased in 
eosinophilic asthma [Wenzel et al., 1999] and Th2-high asthma [Dougherty et al., 2010], 
whereas mast cells numbers are normal in the sub-mucosal of patients with severe non-
eosinophilic asthma [Wenzel et al., 1999] and in the epithelium of non-smoker with Th2-low 
asthma [Dougherty et al., 2010].  Mast cell numbers in airway smooth muscle are increased in 
both non-eosinophilic and eosinophilic asthma  [Berry et al., 2007]. Bronchial biopsy neutrophil 
numbers are increased to a similar degree in non-eosinophilic severe asthma and eosinophilic 
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severe asthma [Wenzel et al., 1999]. Neutrophil numbers in Th2-low asthma have not been 
reported. A lower proportion of subjects with non-eosinophilic asthma are atopic compared to 
eosinophilic asthma (18% versus 66%) [Berry et al., 2007] and (58% versus 83%) [Gibson et al., 
2001]. Severe asthma associated with neutrophilia has significantly higher sputum levels of 
Th17-related cytokines (CXCL1, CXCL10 , CCL2, IL-6, and IL-8) compared with severe asthmatics 
with other inflammatory phenotypes [Manni et al., 2014]. The proportion of Th17 lymphocytes 
and the ratio of Th17 to regulatory T cells (Treg) in the peripheral blood is greater in patients 
with non-eosinophilic asthma taking inhaled corticosteroids compared to an eosinophilic 
asthma group [Furukawa et al., 2015]. Approximately one third of patients with severe 
eosinophilic asthma have a Th17-high signature that is associated with a Th2-low gene 
expression profile [Choy et al., 2015].  The number of subjects with non-eosinophilic severe 
asthma in this study was not sufficient to determine their Th17 profile [Choy et al., 2015]. 
Taken together, these finding suggest that non-eosinophilic inflammation and Th2-low 
inflammation in non-smokers with asthma share some similar immunopathological features 
including normal eosinophil numbers, submucosal mast cell numbers and sub-epithelial 
basement membrane thickness. There is a need for further studies to establish the similarities 
and differences in endotypes of non-eosinophilic, Th2-low and Th17 high inflammation to help 
identify sub-groups of patients for targeted therapies. 
 
Factors accounting for neutrophilic airway inflammation in asthma 
 
Several factors either alone or in combination could explain raised sputum neutrophil counts in 
asthma (Table 1). Firstly, corticosteroids inhibit apoptosis of neutrophils [Cox, 1995] and  their 
use in asthma may contribute to sputum neutrophilia [Saffar et al., 2011]. In addition, Th2-
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targeted therapies, including oral corticosteroids may contribute to the development of Th17-
high neutrophilic inflammation [Choy et al., 2015, Shum, 2015].  In support of corticosteroids 
causing neutrophilia in asthma , inhaled corticosteroid withdrawal from patients with moderate 
asthma resulted in only one subject with neutrophilic inflammation although the reintroduction 
of inhaled fluticasone for 4 weeks resulted in a raised neutrophil count in only 5% of subjects 
[Cowan et al., 2010]. In one study of patients with severe oral corticosteroid dependent asthma 
associated with increased sputum neutrophil number,  markers of neutrophil activation 
including oxidative burst and surface granular receptor expression were similar to patients with 
mild asthma [Nair et al., 2015]. In the SARP cohort, however corticosteroid use was not 
associated with sputum neutrophilia, suggesting that continuous corticosteroid exposure may 
not be the only influence on sputum neutrophil numbers in severe asthma [Moore et al., 2014].  
Secondly, co-morbid conditions such bronchiectasis or severe airflow obstructions occurring in 
association with asthma may result in neutrophilic inflammation. Thirdly, delayed human 
neutrophil apoptosis has been reported in severe asthma [Uddin et al., 2010], possibly due to 
epithelial growth factor induced release of mediators with neutrophil chemotactic and anti-
apoptotic actions from bronchial epithelial cells [Uddin et al., 2010, Uddin et al., 2013]. 
Fourthly, macrophage efferocytosis is impaired in non-eosinophilic asthma, which may cause 
airway neutrophilia [Simpson et al., 2013]. Fifthly, altered airway microbiome has been 
implicated in airway neutrophilia. Airway colonisation determined by terminal restriction 
fragment length polymorphism (T-RFLP) analysis is associated with more severe airways 
obstruction and longer duration of disease as well as neutrophilic airway inflammation and 
raised sputum IL-8 levels [Simpson et al., 2013, Green et al., 2014]. Taken together, these 
finding suggest that the cause of airway neutrophilia in asthma is likely to be complex, possibly 
due to corticosteroid treatment inducing impaired apoptosis of neutrophils and Th17 mediated 
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neutrophilic inflammation, delayed apoptosis of neutrophils due to epithelial growth factor 
release and ineffective macrophage efferocytosis of neutrophils  as well as an altered airway 
microbiome. 
 
Clinical phenotypes associated with non-eosinophilic inflammation  
 
Non-eosinophilic inflammation, either paucigranulocytic or neutrophilic occurs in a range of 
clinical phenotypes that account for approximately 50% of adults never or ex-smokers with mild 
to severe asthma or that have controlled or uncontrolled asthma (Table 2). Non-eosinophilic 
inflammation, with or without neutrophilic inflammation is commonly found in smokers with 
asthma [Chalmers et al., 2002, Boulet et al., 2006, Thomson et al., 2013]. A high BMI is 
associated with non-eosinophilic asthma in some people [Haldar et al., 2008], although others 
have submucosal eosinophilia [Desai et al., 2013] . Approximately two thirds of cases of 
occupational asthma due to low molecular weight agents have non-eosinophilic inflammation 
[Anees et al., 2002], which is associated with a poor asthma prognosis [Lemiere et al., 2014]. 
Non-occupational-induced asthma that is exacerbated by work exposures is associated with 
non-eosinophilic phenotype [Lemière et al., 2013].  Additional factors associated with higher 
neutrophil counts include older age [Brooks et al., 2013], exposure to environmental pollution 
through living close to car pollution [Wallace et al., 2011], exposure to occupational particulate 
matter [Simpson et al., 2015] and respiratory infections. 
 
Biomarkers that can identify non-eosinophilic airway inflammation 
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Are there biomarkers that can identify patients with non-eosinophilic airway inflammation? 
Blood eosinophil numbers are moderately associated with sputum eosinophils [Schleich et al., 
2013, Zhang et al., 2014, Wagener et al., 2015].  Using a cut-off for a blood eosinophil count of 
>0.22 x 10
9
/L 
3 
[Schleich et al., 2013], >0.26 x 10
9
/L [Zhang et al., 2014] or >0.27 x 10
9
/L 
[Wagener et al., 2015] accurately predicts sputum eosinophilia. In contrast, another study 
reported that blood eosinophils had a poor predictive value of 47% for sputum eosinophilia 
(>3% cut-off) although this was better in severe asthma (71%) [Hastie et al., 2013]. In patients 
with mild to severe asthma, blood eosinophils were reported to be better than serum periostin 
and exhaled nitric oxide in identifying sputum eosinophilia [Wagener et al., 2015]. Blood 
neutrophil numbers has a weak relationship with sputum neutrophil count [Schleich et al., 
2013, Zhang et al., 2014] and they have a poor predictive value for sputum neutrophilia (64% or 
38%  for a cut-off of >40% or >61% cut-off respectively) [Hastie et al., 2013]. In one study 
exhaled nitric oxide predicted inhaled corticosteroid response for airway hyperreactivity in non-
eosinophilic asthma (area under the curve 0.81), with an optimum cut-off point of 33 ppb 
[Cowan et al., 2010].  
 
Which inflammatory phenotype to target? 
 
In summary, non-eosinophilic airway inflammation is found in approximately 50% of patients 
with mild to severe asthma. The proportion of this group with neutrophilic inflammation is less 
certain because of variable cut-off points used in different studies to define neutrophilia. 
Current symptoms, rate of exacerbations and rate of decline in lung function are generally less 
severe in non-eosinophilic asthma compared to eosinophilic asthma. Non-eosinophilic 
inflammation is associated with an impaired response to inhaled corticosteroids. There is some 
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evidence that neutrophils are activated in the airways of patients with neutrophilic asthma and 
that biomarkers of systemic inflammation is increased in this group. Neutrophilia in asthma 
may be due to corticosteroids, associated chronic pulmonary infection, altered airway 
microbiome and/or delay neutrophil apoptosis, particularly in severe disease. Non-eosinophilic 
asthma and Th2-low asthma may share some common immunopathological features, but 
further investigation is required. Due to the lack of effective specific therapies targeting non-
eosinophilic inflammation including neutrophilic inflammation there is currently no definitive 
evidence for the involvement of these inflammatory phenotypes in chronic asthma. Additional 
pathways may account for poor asthma control in patients with non-eosinophilic asthma 
including Th1 inflammation, Th17 inflammation, or a combination of  Th2 and Th17 
inflammation as well as  corticosteroid insensitivity (Figure 1). Recent work suggests a 
reciprocal relationship between Th2 and Th17 pathways in severe disease and that 
corticosteroid treatment may contribute to the emergence of a Th17-high profile [Choy et al., 
2015]. Non-inflammatory mechanisms may also be important in some individuals including 
airway hyperreactivity and airway remodelling.  
 
TREATMENTS TARGETING NON-EOSINOPHILIC AIRWAY INFLAMMATION 
 
Many patients with asthma continue to have poorly controlled disease despite treatment with 
currently available therapies. There is an unmet need for novel treatments that will impact 
favourably on clinical outcomes in patients with non-eosinophilic inflammation.  Non-
pharmacological interventions, ‘off-label’ use of licensed drugs, novel small molecules and 
biologics agents are being investigated as possible treatments of non-eosinophilic inflammation 
in asthma (Table 3 and Figure 2).  
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Non-pharmacological interventions  
 
Avoidance from exposure to environmental and occupational pollutants may reduce 
neutrophilic inflammation in asthma. In a study of smokers with asthma of whom a 
subgroup quit smoking for 6 weeks the proportion of sputum neutrophils reduced, 
corticosteroid sensitivity improved  and the FEV1 increased compared to those who 
continued to smoke [Chaudhuri et al., 2006]. After cessation of exposure to occupational 
agents, neutrophilic inflammation reduced in people in whom their asthma was cured or 
improved compared to those in whom there was no improvement [Maghni et al., 2004].  
Several clinical trials have examined the effect of dietary supplement of vitamin D in asthma, 
based on the anti-inflammatory and corticosteroid-enhancing actions of vitamin D [Nanzer et al., 
2013, Zhang et al., 2014] [Xystrakis et al., 2006].  Two large randomized clinical trials of vitamin 
D3 supplementation in patients with asthma and vitamin D insufficiency [VIDA and ViDiAs trials), 
although not selected for specific airway inflammatory cell profiles or corticosteroid insensitivity, 
reported no improvements in clinical outcomes [Castro et al., 2014, Martineau et al., 2015, 
Denlinger et al., 2015 ]. Interestingly, vitamin D supplementation reduces eosinophilic 
inflammation in patients with non-atopic asthma, suggesting that certain inflammatory 
phenotypes might benefit from vitamin D3 supplementation [De Groot et al., 2015]. 
 
‘Off-label’ use of licensed drugs 
 
Several drugs licensed for the treatment of medical conditions other than asthma have been 
investigated for their efficacy in asthma, including patients with non-eosinophilic inflammation. 
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Candidate drugs have been chosen usually because of pre-clinical evidence of anti-
inflammatory effects that might be relevant to treatment of asthma. Some examples are 
reviewed below. 
 
Macrolides 
 
Macrolides may be of benefit in the treatment of chronic asthma [Reiter et al., 2013], including 
non-eosinophilic asthma [Simpson et al., 2008], although prescribing macrolides as a long-term 
treatment increases the risk  of adverse drug effects and the development of microbial 
resistance [Cameron et al., 2012]. The mechanism(s) of action of macrolides in the treatment of 
airway diseases is not known, but could be due to antibacterial and/or anti-inflammatory 
actions, which include inhibition of NF-κB and other transcription factors as well as  reduction in 
neutrophil migration and/or function [Culic et al., 2001, Fujitani et al., 2003, Simpson et al., 
2008, Cameron et al., 2012, Kobayashi et al., 2013]. Macrolides have additional potentially 
beneficial properties including anti-viral actions [Gielen et al., 2010, Schögler et al., 2015] and 
an ability to restore corticosteroid sensitivity by inhibiting the phosphoinositide 3-kinase (PI3K) 
pathway and restoring histone deacetylase (HDAC)2 activity [Spahn et al., 2001, Kobayashi et 
al., 2013, Hao et al., 2015] and by attenuating TNFα and IL-17 immune responses [Essilfie et al., 
2015]. Two recent exploratory clinical trials have investigated the effects of macrolides in non-
eosinophilic asthma. In one trial, smokers with mild to moderate asthma associated with non-
eosinophilic inflammation were randomized to azithromycin 250 mg per day or placebo 
[Cameron et al., 2013].  After 12 weeks, treatment with azithromycin was not associated with 
improvements in morning PEF, ACQ score, AQLQ score and methacholine PC20 compared to 
placebo and did not alter induced sputum differential counts, bacterial load, C. pneumonia, M. 
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pneumoniae seropositivity or upper airways respiratory virus prevalence. In an other 
randomized controlled trial patients with exacerbation-prone severe asthma received low-dose 
azithromycin or placebo as add-on treatment to combination therapy of inhaled corticosteroids 
and long-acting β2 agonists for 6 months [Brusselle et al., 2013]. The rate of severe 
exacerbations and lower respiratory tract infections requiring treatment with antibiotics was 
not reduced by azithromycin. In a predefined subgroup with non-eosinophilic severe asthma 
(blood eosinophilia ≤200/µl) there was a reduction in the rate of primary endpoints in 
azithromycin-treated patients [Brusselle et al., 2013]. Azithromycin improved AQLQ scores, but 
did change ACQ scores or lung function. Based on these findings, further clinical trials of 
macrolides in non-eosinophilic severe asthma are indicated. Novel analogues of macrolides 
have been developed that have enhanced anti-inflammatory properties than current 
macrolides, such as solithromycin (CEM-101) [Kobayashi et al., 2013, Kobayashi et al., 2013] or 
that lack anti-bacterial properties, such as the non-antibiotic azithromycin derivative CSY0073 
[Balloy et al., 2014].  
 
Statins 
 
Statins have pleiotropic immunomodulatory actions [Greenwood et al., 2006] that may of 
value in the treatment of chronic inflammatory diseases [Greenwood et al., 2006, Hothersall 
et al., 2006, Yeganeh et al., 2014]. In experimental models of allergic asthma [Mckay et al., 
2004, Zeki et al., 2009] and tobacco-smoke-induced lung inflammation [Lee et al., 2005, 
Davis et al., 2013] statins reduce inflammatory pathways potentially relevant to the 
pathogenesis of asthma and smoke-induced airway diseases. Statins might also restore 
corticosteroid sensitivity in asthma [Samson et al., 2006, Maneechotesuwan et al., 2010]. 
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Taken together, these findings suggest that statin treatment may have anti-inflammatory 
effects in people with asthma including smokers with asthma. A randomized double-blind 
parallel group trial undertaken in seventy one smokers with mild to moderate asthma 
associated with non-eosinophilic inflammation compared treatment with atorvastatin 40 mg 
per day with placebo. After 4 weeks treatment inhaled beclometasone 400 μg per day was 
added to both treatment arms for a further 4 weeks [Braganza et al., 2011]. At 4 weeks, 
there was an improvement in ACQ and AQLQ scores with atorvastatin, but not in lung 
function. There was no significant improvement with atorvastatin and inhaled 
beclometasone compared to inhaled beclometasone alone in clinical outcome measures at 
8 weeks. In a follow-up study the effects of atorvastatin alone and in combination with 
inhaled corticosteroid was investigated on their ability to suppress the concentration of a 
range of cytokines, chemokines and growth factors in sputum samples collected during the 
previous clinical trial [Braganza et al., 2011, Thomson et al., 2015 ].  Sputum mediator 
concentrations were not reduced by inhaled beclometasone alone. Atorvastatin significantly 
reduced sputum concentrations of CCL7, IL-12p70, sCD40L, FGF-2, CCL4, TGF-α and MMP-8 
compared with placebo and, when combined with inhaled beclometasone, reduced sputum 
concentrations of MMP-8, IL-1β, IL-10, MMP-9, sCD40L, FGF-2, IL-7, G-CSF and CCL7 
compared to ICS alone. Improvements in ACQ and/or AQLQ scores with atorvastatin and 
inhaled beclometasone were associated with decreases in G-CSF, IL-7, CCL2 and CXCL8. 
Interestingly, simvastatin suppresses airway IL-17 and upregulated IL-10 in patients with 
stable COPD [Maneechotesuwan et al., 2013]. Taken together, these findings suggest that 
short-term treatment with atorvastatin alone or in combination with inhaled 
beclometasone reduces several sputum cytokines, chemokines and growth factors 
concentrations unresponsive to inhaled corticosteroids alone in asthmatic smokers with 
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non-eosinophilic inflammation. There is a need for long-term clinical studies examining 
effect of statins on exacerbations and airway remodelling in chronic non-eosinophilic 
asthma. 
 
Low-dose theophylline 
 
Low dose theophylline has been shown to restore corticosteroid sensitivity in-vitro possibly 
by increasing HDAC-2 activity, which is suppressed in severe asthma and in smokers with 
asthma and a similar clinical effect might occur in people with severe disease or who are 
smokers [Barnes, 2009, To et al., 2010]. Theophylline inhibits oxidative stress dependent 
PI3K-δ activation and restores corticosteroid sensitivity in PBMCs from patients with COPD 
[To et al., 2010]. An exploratory clinical trial examined the effects of low dose theophylline 
added to inhaled  beclometasone compared to inhaled beclometasone alone in smokers 
with asthma associated with non-eosinophilic inflammation [Spears et al., 2009].   The 
addition of low dose theophylline to inhaled beclometasone, at a dose titrated to provide a 
‘sub-therapeutic’ concentration, resulted in increased efficacy as measured by lung function 
and suggested the restoration of corticosteroid sensitivity in those treated with the 
combination. Clinical trials to date have not investigated the therapeutic effects of adding 
low dose theophylline to patients with severe asthma. A fixed combination of ultra-low dose 
of theophylline with fluticasone, SKP-2075 (Skepharma), in a dry powder inhaler is under 
development for the treatment COPD. This combination would potentially be of benefit in 
the treatment of severe asthma and smokers with asthma, possibly in those people with 
non-eosinophilic inflammation. 
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PPARγ agonist 
 
In pre-clinical studies peroxisome proliferator-activated receptor-γ (PPARγ) agonists exert anti-
inflammatory effects potentially relevant to the treatment of inflammatory airway diseases 
including asthma and COPD [Spears et al., 2006, Belvisi et al., 2008, Seidel et al., 2012, Stephen 
et al., 2013, Bourke et al., 2014, Lakshmi et al., 2014, Lea et al., 2014, Donovan et al., 2015 ]. 
For example, PPARγ agonists reduce eosinophilic and neutrophilic lung infiltration in 
experimental animal models exposed to  allergen or tobacco smoke [Bauer et al., 2010, Lea et 
al., 2014, Zhao et al., 2014, Morissette et al., 2015]. The oral PPARγ agonist rosiglitazone had a 
modest effect in attenuating the allergen-induced late asthmatic response [Richards et al., 
2010]. A further proof of concept study reported that rosiglitazone compared with inhaled 
beclometasone dipropionate resulted in improvement in lung function and a borderline 
reduction in sputum IL-8 concentration in smokers with mild to moderate asthma that was 
associated with non-eosinophilic inflammation [Spears et al., 2009]. The oral PPARγ agonist 
pioglitazone is not effective in obese asthmatics [Dixon et al., 2015].  Inhaled PPARγ agonist 
analogues, such as AD3277 (Pulmagen) are under development for the treatment of chronic 
inflammatory airway diseases and potentially might be of benefit in non-eosinophilic asthma.  
 
Novel small molecule drugs  
 
Novel small molecule inhibitors have been developed for treating neutrophilic/non-eosinophilic 
asthma including CXCR2 antagonists, FLAP inhibitors, PDE4 inhibitors, dual PDE3 and PDE4 
inhibitor and various protein kinase inhibitors. 
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CXCR2 antagonist 
 
CXCR2 receptors are expressed on neutrophils as well as on airway goblet cells, fibroblasts 
and airway smooth muscle [Chapman et al., 2009]. Ligands for the CXCR2 receptor include 
the chemokines CXCL8 (IL-8), growth-related protein (Gro)-α, -β, and -γ (CXCL1–3), 
epithelial-derived neutrophil attractant-78 (ENA-78; CXCL5), granulocyte chemotactic 
protein-2 (GCP-2; CXCL6) and neutrophil- activating peptide-2 (NAP-2; CXCL7) [Chapman et 
al., 2009, Campbell et al., 2013]. Activation of  CXCR2 receptors result in neutrophil 
chemotaxis, proteases production, aairway goblet cell hyperplasia, pulmonary blood vessel 
angiogenesis, collagen deposition and airway smooth muscle contraction and  migration 
[Chapman et al., 2009]. The effects of CXCR2 antagonists have been studied on airway 
challenges that induce sputum neutrophilia. The CXCR2 antagonist, AZD8309 inhibits LPS-
induced airway neutrophilic inflammation in healthy volunteers [Leaker et al., 2013] and the 
CXCR2 antagonist, SB656933 inhibited ex vivo neutrophil activation and ozone-induced 
airway inflammation in humans [Lazaar et al., 2011]. The CXCR2 antagonist, SCH527123 
inhibits ozone-induced neutrophilia in healthy subjects [Holz et al., 2010]. A randomized, 
placebo-controlled clinical trial of the CXCR2 antagonist SCH527123 administered for 4 
weeks to patients with severe asthma and sputum neutrophils > 40% resulted in a reduction 
of 36.3% in sputum neutrophil percentage, fewer mild exacerbations and a trend towards 
improvement in ACQ score [Nair et al., 2012]. A clinical trial of the efficacy and safety of a 
CXCR2 antagonist AZD5069 in severe, uncontrolled persistent asthma reported that the 
addition of AZD5069 to combination ICS/LABA treatment did not improve clinical outcomes 
despite a dose-dependent reduction in blood neutrophil counts [O'byrne et al., 2015]. A lack 
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of improvement in clinical outcome despite a reduction in sputum neutrophil counts was 
reported with the CXCR2 antagonist AZD5069 in bronchiectasis [De Soyza et al., 2015]. A 
recent trial of the CXCR2 antagonist Navarixin (SCH527123) in COPD led to significant 
improvements in FEV1 and reduction in sputum neutrophil count, particularly in current 
smokers with COPD [Rennard et al., 2015].   The CXCR2 antagonist AZD8309 administered 
for 4 weeks to patients with moderate to severe COPD was well tolerated with no increase 
in the rate of infections [Kirsten et al., 2015]. A small-molecule oral CXCR2 antagonists 
Danirixin (GSK1325756) is undergoing a clinical trial in patients with COPD at risk of 
exacerbations (ClinicalTrials.gov Identifier: NCT02130193). Oral CXCR2 antagonists could 
potentially cause neutropenia, and the therapeutic index of these compounds requires 
careful assessment. 
 
FLAP inhibitors 
 
Pro-inflammatory cysteinyl leukotrienes (LTs) are synthesised from arachidonic acid in 
inflammatory cells by 5-lipoxygenase (LO) and 5-lipoxygenase activating protein (FLAP). 
FLAP inhibitors such as GSK-2190915 [Evans et al., 2008] prevent the formation of LTB4, 
which may be of value in  the treatment of neutrophilic asthma. GSK2190915 markedly 
inhibited ex vivo calcium ionophore stimulated blood LTB4 formation and urinary 
leukotriene E4 (LTE4) formation [Bain et al., 2013]. Pre-treatment with GSK2190915 reduces 
the early and late phase response to allergen challenge and results in a significant reduction 
of sputum LTB4 levels [Kent et al., 2013]. Despite suppressing the target mediator LTB4, the 
FLAP inhibitor GSK2190915 has no short-term effect on sputum cell counts or clinical 
endpoints in smokers and non-smokers with asthma associated with neutrophilic 
Page 27 of 126
http://mc.manuscriptcentral.com/TAR
Therapeutic Advances in Respiratory Disease
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 Management of non-eosinophilic asthma  27 
 
inflammation (sputum neutrophilia ≥ 50% for one sample and >45% for the other), 
suggesting that LTB4 suppression alone is inadequate in controlling airway neutrophils in 
asthma [Chaudhuri et al., 2014]. No active clinical trials of FLAP inhibitors in asthma are 
currently registered on ClinicalTrials.gov. 
 
PDE4 inhibitors and dual PDE3 and PDE4 inhibitors 
 
Phosphodiesterase (PDE)4 inhibitors have immunomodulatory effects on inflammatory cells 
potentially relevant to the treatment of asthma [Lipworth, 2005, Page et al., 2012, Kim et 
al., 2015 ]. In an allergen challenge study the oral PDE4 inhibitor roflumilast attenuated the 
rise in sputum eosinophils and neutrophils numbers after the late asthmatic response 
[Gauvreau et al., 2011]. High doses of PDE4 inhibitors may be necessary to treat severe 
asthma, and gastro-intestinal side effects limit their use [Lipworth, 2005, Bateman et al., 
2006, Bousquet et al., 2006]. The inhaled administration of PDE4 inhibitors may improve the 
therapeutic index of PDE4 inhibitors [Chapman et al., 2010, Singh et al., 2010, Nials et al., 
2011, De Savi et al., 2014, Moretto et al., 2015]. Inhaled PDE4 inhibitors GSK256066 and 
CHF6001 both inhibit allergen-induced late asthmatic responses [Singh et al., 2010, Dave et 
al., 2014] and in patients with moderate COPD  inhaled GSK256066 for 4 weeks was well 
tolerated although there was no inhibitory effect on sputum and blood inflammatory 
biomarkers [Watz et al., 2013]. The inhaled dual PDE3 and PDE4 inhibitor RPL554 (Verona 
Pharma) has bronchodilator effects and is well tolerated in patients with asthma and COPD 
[Franciosi et al., 2013]. In healthy subjects inhaled RPL554 attenuates the neutrophilic 
response to LPS challenge [Franciosi et al., 2013]. RPL554 is under development for the 
Page 28 of 126
http://mc.manuscriptcentral.com/TAR
Therapeutic Advances in Respiratory Disease
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 Management of non-eosinophilic asthma  28 
 
treatment of asthma and COPD (ClinicalTrials.gov Identifier: NCT02427165 and 
NCT02542254 respectively). 
 
Protein kinase inhibitors 
 
Protein kinases are involved in cellular signalling of pro-inflammatory cytokines in asthma 
and the inhibition of these kinases may have a role in the treatment of severe asthma 
associated with non-eosinophilic asthma [Bhavsar et al., 2010, Cohen et al., 2010, 
Hammaker et al., 2010, Chung, 2011, Guntur et al., 2012].  Several p38MAPK inhibitors 
restore corticosteroid sensitivity in PBMCs from patients with severe asthma [Bhavsar et al., 
2010, Mercado et al., 2012] and COPD [Khorasani et al., 2015]. Clinical trials of  p38MAPK 
inhibitors oral losmapimod (GW856553) and inhaled AZD7624 are register for the treatment 
COPD (ClinicalTrials.gov Identifier: NCT02299375 and NCT02238483 respectively), although 
neither are registered for the treatment of asthma. Interestingly, a post-hoc analysis of a 6 
month clinical trial of oral losmapimod (GW856553) in COPD reported a reduction in 
exacerbations in a sub-group of patients with a blood eosinophil count <2% [Marks-
Konczalik et al., 2015], which may suggest a preferentially beneficial effect of p38MAPK 
inhibitors in non-eosinophilic inflammation. A imatinib, a specific ckit tyrosine kinase 
inhibitor that attenuates airway hyperresponsiveness, inflammation and remodelling in 
murine model of asthma [Berlin et al., 2005, Rhee et al., 2011] is under development for 
patients with severe refractory asthma (ClinicalTrials.gov Identifier: NCT01097694). A 
tyrosine kinase inhibitor masitinib targets c-kit and platelet-derived growth factor (PDGF) 
receptor improved asthma control in patients with severe corticosteroid-dependent asthma 
[Humbert et al., 2009] and a further clinical trial underway in patients with severe asthma 
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treated with oral corticosteroids (ClinicalTrials.gov Identifier:  NCT01449162). An alternative 
therapeutic strategy  to silencing c-kit with small interference RNA has been shown to  
attenuate inflammation in a murine model of allergic asthma [Wu et al., 2012, Wu et al., 
2014]. Clinical trials of protein kinase inhibitors have not been studied in patients with 
sputum inflammatory subtypes such as non-eosinophilic asthma. 
 
PI3kinase inhibitors 
 
Low dose theophylline is thought to act, at least in part, through the inhibition of PI3K [Ito et 
al., 2007, To et al., 2010]. Pre-clinical studies suggest that PI3K-δ inhibitors could potentially 
reverse corticosteroid insensitivity by increasing HDAC2 activity [Marwick et al., 2009, Marwick 
et al., 2010] and by reversing fungal-induced steroid resistant airway inflammation through 
modulation of endoplasmic reticulum stress [Lee et al., 2016]. Selective PI3K inhibitors are 
being developed as novel therapies for the treatment of chronic inflammatory airway diseases. 
An inhaled PI3Kδ inhibitor GSK2269557 is undergoing several clinical trials in asthma and COPD.  
PI3K δ and γ isoforms are involved in inflammatory cell recruitment and activation and dual 
PI3Kδ/γ inhibitors, such as TG100-115 and IPI-145 reduces airway inflammation induced by 
allergen or cigarette smoke in murine models [Doukas et al., 2009, Winkler et al., 2013] and 
restored corticosteroid sensitivity in the smoke model [Doukas et al., 2009]. RV1729,  a PI3Kδ/γ 
Inhibitor has undergone early stage clinical evaluation in asthma and COPD. SH2-containing 
inositol-50-phosphatase 1 (SHIP1) is an endogenous inhibitor of the PI3K pathway. A SPIP1 
activator AQX-1125 reduced the allergen-induced late asthmatic response with a non-
significant trend for a reduction in sputum eosinophils and neutrophils [Leaker et al., 2014]. 
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Further development of AQX-1125 is underway for the treatment of COPD (ClinicalTrials.gov 
Identifier: NCT01954628). 
 
Biological agents  
 
Monoclonal antibody blockers of inflammatory cytokines such as IL-17 and TNF-α that activate 
receptors on the surface of neutrophils have been investigated as treatments for asthma. 
 
IL-17 blockers 
 
In pre-clinical studies Th17 cells and IL-17 are implicated in causing neutrophilic inflammation 
and corticosteroid insensitivity [Shen et al., 2011, Newcomb et al., 2013, Chesné et al., 
2014]. IL-17 concentrations and expression are increased in BAL, sputum and bronchial 
biopsy samples in severe patients asthma that correlate with sputum neutrophils. 
Monoclonal inhibitors of IL-17 are in clinical development [Miossec et al., 2012]. 
Brodalumab is a human monoclonal antibody that binds with high affinity to human IL-
17RA, blocking the biologic activity of IL-17A, -17F, -17A/F heterodimer, and IL-25. A 
randomized clinical trial of  brodalumab in adults with inadequately controlled moderate to 
severe asthma receiving regular inhaled corticosteroids, but not selected for neutrophilic 
inflammation, reported no improvement in the primary outcome ACQ score or in  lung 
function and symptom-free days [Busse et al., 2013]. A subgroup with high bronchodilator 
reversibility demonstrated a borderline improvement an ACQ score. A further clinical trial of 
brodalumab in inadequately controlled asthma subjects with high bronchodilator 
reversibility was recently terminated due to a lack of observed efficacy in a pre-specified 
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interim analysis (ClinicalTrials.gov Identifier: NCT01902290). The results of a preliminary 
proof of efficacy study of the IL-17A monoclonal antibody blocker secukinumab (AIN457) in 
patients with uncontrolled asthma was also recently terminated. The investigators report 
that further investigations would require changes in study design, the use of different 
endpoints, a different IL-17 antibody or a different patient population (ClinicalTrials.gov 
Identifier: NCT01478360). 
 
TNF-α blockers 
 
Neutralizing TNFα restores corticosteroid sensitivity in a mouse model of neutrophilic airway 
inflammation [Dejager et al., 2015 ]. Several small clinical studies in severe asthma  of the 
soluble TNF-α receptor blocker etanercept reported beneficial effects on clinical outcomes 
[Howarth et al., 2005, Berry et al., 2006], whereas larger studies with etanercept [Holgate et al., 
2011] and the TNF-α receptor blocker golimumab [Wenzel et al., 2009] did not confirm a 
consistent beneficial clinical effect. When combined with concerns over increased risk of severe 
infections and malignancies with TNF-α receptor blocker treatment [Wenzel et al., 2009] it is 
unlikely that this target  will be developed further for the treatment of asthma. 
 
Other monoclonal antibodies 
  
Monoclonal antibodies that block IL-1β, for example, canakinumab or block the soluble IL-1 
receptor, for example, anakinra [Hernandez et al., 2015] might be of benefit in neutrophilic 
asthma, although no clinical studies are currently registered. An IL-6 monoclonal antibody 
blocker toclizumab is licensed for the treatment of rheumatoid arthritis. Toclizumab could 
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potentially be of benefit in neutrophilic asthma although no clinical studies are registered in 
asthma. 
 
Conclusions and future developments 
 
Non-eosinophilic airway inflammation is a term used to describe a subtype of asthma 
associated with normal numbers of sputum eosinophils. Up to 50% of patients with stable mild 
to severe never or ex-smokers with asthma have non-eosinophilic inflammation and this 
inflammatory phenotype is also found in smokers with asthma, some patient with a high BMI or 
occupational asthma. The non-eosinophilic phenotype is subdivided into neutrophilic 
inflammation, when neutrophil numbers are raised above a defined cut-off level or 
paucigranulocytic inflammation, when both eosinophil and neutrophil numbers are normal. The 
relative proportions  of each subtype is uncertain because of variable cut-off points used to 
define neutrophilia. The most appropriate value that indicates that neutrophils are activated 
and contributing to the pathogenic processes in asthma is not certain. The severity of current 
symptoms are in general similar or slightly better in non-eosinophilic or neutrophilic subgroups 
of asthma compare to eosinophilic subgroups. Sputum eosinophilia is a better predictor of 
future exacerbations and a greater risk factor for more rapid decline in lung function than 
sputum neutrophilia. Non-eosinophilic inflammation is associated with an impaired therapeutic 
response to inhaled corticosteroids. Neutrophilic inflammation is associated with activation of 
the innate immune system in asthma and systemic inflammation. Several mechanisms either 
alone or in combination could explain raised sputum neutrophil counts in asthma including 
corticosteroids, associated chronic sinopulmonary infection, delay human neutrophil apoptosis 
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due to epithelial growth factor, impaired macrophage phagocytosis and altered airway 
microbiome. Limited information has been published on the immunopathological 
characteristics of non-eosinophilic inflammation compared with other inflammatory airway 
phenotypes including Th2-low inflammation, Th17-high inflammation or combination of 
Th2/Th17 profiles in asthma. Taken together, the finding suggest that non-eosinophilic 
inflammation and Th2-low inflammation in non-smokers with asthma share some similar 
immunopathological features including normal eosinophil numbers, submucosal mast cell 
numbers and sub-epithelial basement membrane thickness. Due to the lack of effective specific 
therapies targeting non-eosinophilic inflammation including neutrophilic inflammation there is 
currently no definitive evidence for the involvement of these inflammatory phenotypes in 
chronic asthma. Additional pathways may account for poor asthma control in patients with 
non-eosinophilic asthma including Th1 inflammation, Th17 inflammation, or a combination of  
Th2 and Th17 inflammation as well as  corticosteroid insensitivity (Figure 2). The role of 
corticosteroid treatment in causing neutrophilic and Th17 inflammation in severe asthma 
requires further investigation. Non-inflammatory mechanisms may also be important in some 
individuals including airway hyperreactivity and airway remodelling.  
 
There is an unmet need for novel treatments that will impact favourably on clinical outcomes in 
patients with non-eosinophilic inflammation.  Non-pharmacological interventions, ‘off-label’ 
use of licensed drugs, novel small molecules and biologics agents are being investigated as 
possible treatments of non-eosinophilic inflammation in asthma. Smoking cessation in smokers 
with asthma and cessation of exposure to occupational agents are associated with a reduction 
in neutrophilic inflammation. Preliminary data of studies of ‘off-label’ use of licensed drugs 
suggest that macrolides show efficacy in non-smokers with non-eosinophilic asthma and 
Page 34 of 126
http://mc.manuscriptcentral.com/TAR
Therapeutic Advances in Respiratory Disease
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 Management of non-eosinophilic asthma  34 
 
statins, low-dose theophylline and PPARγ agonist may be beneficial in asthmatic smokers with 
non-eosinophilic inflammation and corticosteroid insensitivity. Further clinical studies are 
indicated to confirm these findings and to determine the role of these therapies in the 
management of severe asthma. Novel small molecules targeting neutrophilic inflammation in 
asthma such as CXCR2 antagonists reduce neutrophil counts, but do not improve clinical 
outcomes. A FLAP inhibitor did not reduce neutrophils or improve symptoms. Inhaled PDE4 
inhibitors and dual PDE3 and PDE4 inhibitors are potential therapies for neutrophilic asthma 
and a dual PDE3 and PDE4 inhibitors is under development for the treatment of asthma and 
COPD. Additional small molecule drugs including p38MAPK inhibitors, tyrosine kinase inhibitors 
and PI3kinase inhibitors are under development for asthma. The development of biological 
agents to target non-eosinophilic inflammation in asthma has been disappointing to date with 
the termination of clinical programmes of monoclonal antibodies targeting IL-17 and TNF-α. In 
the future, the selection of patients with severe asthma and evidence of Th17-high 
inflammation may be more likely to identify a subpopulation that respond to IL-17 blockers. 
Long-acting bronchodilators and/or bronchial thermoplasty are possible treatment options for 
symptomatic patients with paucigranulocytic inflammation in whom there is no evidence of 
activated inflammatory pathways or corticosteroid insensitivity that could be targeted by 
specific therapies. 
 
Greater understanding of the mechanisms of non-eosinophilic inflammation in asthma should 
lead to improved therapies. International collaborative programmes of research investigating 
pathogenic mechanism of severe asthma have focused mainly on type 2 eosinophilic 
inflammation. The Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-
BOPRED) study [Gaga et al., 2015, Shaw et al., 2015] and the UK Refractory Asthma 
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Stratification Programme (RASP-UK) [Heaney et al., 2015 ] are designed to identify new 
phenotypes/endotypes and treatment targets and will hopefully identify new approaches to 
the treatment of patients with non-eosinophilic asthma. 
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LIST OF ABBREVIATIONS 
 
ACQ: Asthma control questionnaire 
ACRN: Asthma Clinical Research Network  
AP-1: Activator protein-1  
AQLQ: asthma quality of life questionnaire 
BAL: Bronchoalveolar lavage  
BDP: Beclomethasone dipropionate  
BMI: Body mass index 
CAMP: Childhood Asthma Management Program  
COPD: Chronic obstructive pulmonary disease 
CRHR1: Corticotrophin-releasing hormone receptor 1 gene  
CCL: Chemokine (C-C motif) ligand 
CXCL: Chemokine (C-X-C motif) ligand 
CXCR: C-X-C chemokine receptor 
eNOS: Endothelial nitric oxide synthase  
ERK: Extracellular signal-regulated kinase  
FCER2: Low-affinity IgE receptor gene  
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FGF: Fibroblast growth factor 
FLAP: 5-lipoxygenase-activating protein  
GILZ: Glucocorticoid-inducible leucine zipper 1  
G-CSF: Granulocyte-colony stimulating factor 
GLCCI1: Glucocorticoid-induced transcript 1 gene  
GOAL: Gaining Optimal Asthma Control  
GR: glucocorticoid receptor  
GRE: Glucocorticoid-responsive elements  
HDAC: Histone deacetylase  
HFA: Hydrofluoroalkane  
HMG CoA: 3-Hydroxymethyl-3-glutaryl Coenzyme A  
IDO: Indoleamine 2, 3-dioxygenase  
IFN: interferon  
Ig: immunoglobulin  
IKKs: IκB kinases 
IL: interleukin 
JNK: c-Jun N-terminal kinase  
LABA: Long acting β2-agonists 
LPS: lipopolysaccharide  
LT: leukotriene 
MAPK: Mitogen-activated protein kinase  
MKP: Mitogen-activated protein kinase phosphatase 1 
MMP: Matrix metalloproteinase 
MPO: Myeloperoxidase 
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NO: nitric oxide  
NFκB: Nuclear factor κB  
PEF: Peak expiratory flow  
PBMC: Peripheral blood mononuclear cell  
PDE: Phosphodiesterase  
PI3K: Phosphoinositide 3-kinase  
PP2A: Protein phosphatase 2A  
PPARγ: Peroxisome proliferator-activated receptor-γ  
RASP-UK: Refractory Asthma Stratification Programme  
RBM: Reticular basement membrane thickness 
sCD40L: Soluble CD40 ligand 
SHIP1: SH2-containing inositol-50-phosphatase 1 
SLPI: Secretory leukocyte protease inhibitor expression    
SNPs: Single-nucleotide polymorphisms 
STAT: Signal transduction-activated transcription factors  
SNP: Single nucleotide polymorphisms 
TBX21: T-box expressed in T cells21  
TGF-α: Transforming growth factor alpha 
Th2: Type 2 helper T-cell (Th2) 
TNF-α: Tumour necrosis factor α 
TLR: Toll-like receptor  
U-BOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome  
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Table 1 Possible factors accounting for neutrophilic airway inflammation in asthma 
 
• Corticosteroid treatment causing reduced apoptosis of neutrophils and contributing 
to Th17 mediated neutrophilic inflammation 
• Neutrophila associated with chronic sinopulmonary infection and/or bronchiectasis 
• Delay human neutrophil apoptosis in severe asthma due to epithelial growth factor 
induced release of mediators with neutrophil chemotactic and anti-apoptotic actions 
from bronchial epithelial cells 
• Impaired macrophage phagocytosis of neutrophils 
• Neutophilia associated with altered airway microbiome  
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Table 2 Clinical phenotypes and factors associated with non-eosinophilic airway 
inflammation in asthma 
 
Mild to severe asthma in never or ex-smokers (both controlled and uncontrolled) 
Smokers with asthma 
High BMI (subgroup) 
Occupational asthma (subgroup) 
Factors associated with higher neutrophil counts 
− Older age  
− Exposure to environmental pollution 
− Respiratory infections 
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 Table 3 Treatments targeting non-eosinophilic airway inflammation in asthma 
 
Non-pharmacological interventions  
 
Avoidance from exposure to environmental and occupational pollutants 
Smoking cessation  
Dietary supplementation with vitamin D3 
 
 
‘Off-label’ use of licensed drugs 
 
Macrolides 
Statins 
Low-dose theophylline 
Peroxisome proliferator-activated receptor-γ (PPARγ) agonists  
 
Novel small molecule drugs 
 
Drugs targeting neutrophilic inflammation 
C-X-C chemokine receptor (CXCR)2 antagonists  
5-lipoxygenase-activating protein (FLAP) inhibitors 
 
Phosphodiesterase (PDE) inhibitors  
PDE4 inhibitors  
Dual PDE3 and PDE4 inhibitors  
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Protein kinase inhibitors 
p38 Mitogen-activated protein kinase (MAPK) inhibitors 
Narrow spectrum kinase inhibitors 
Tyrosine kinase inhibitors  
 
Phosphoinositide 3 (PI3)-kinase inhibitors 
PI3K-δ inhibitors  
Dual PI3Kδ/γ inhibitors 
 
Biological agents 
 
Interleukin (IL)-17A receptor blockers 
IL-17A blockers 
Tumour necrosis factor (TNF)-α receptor blockers 
IL-1β monoclonal antibody blockers 
Soluble IL-1 receptor monoclonal antibody blockers 
IL-6 monoclonal antibody blockers 
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FIGURE LEGENDS  
 
Figure 1 Schematic diagram of potential pathways leading to non-eosinophilic   
inflammation and airway damage in severe asthma 
 
Several inflammatory pathways could potentially lead to non-eosinophilic inflammation and 
airway damage in asthma although the exact mechanisms are unclear. Possible pathways 
are briefly summarized in the schematic diagram. Stimuli such as viruses, cigarette smoke 
and pollutants could induce the release of chemoattractants including IL-8 to recruit 
neutrophils to the airways. The release of IL-17A and IL-17F from activated Th17 cells could 
stimulate the synthesis of neutrophil chemoattractants, such CXCL1 and IL-8 from the 
airway epithelium.  INF-γ may also be involved in non-eosinophilic asthma, possibly in part 
through its release from Th1 cells. Inflammatory mediators released by neutrophils are 
implicated in causing  mucus gland hyperplasia and hypersecretion, airway hyperreactivity 
and remodelling as well as corticosteroid insensitivity in asthma. Th1 and Th17 cells may 
induce airway hyperreactivity and/or remodelling independently of neutrophil activation.   
Abbreviations: CXCL1: chemokine (C-X-C motif) ligand; IFN: interferon; IL: interleukin; LT: 
leukotriene; MMP: matrix metalloproteinase; MPO: myeloperoxidase; ROC: reactive oxygen 
species; TNF-α: tumour necrosis factor α 
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Figure 2 Targets and potential therapies for treating non-eosinophilic airway inflammation 
in asthma 
 
Non-eosinophilic airway inflammation is found in approximately 50% of patients with asthma. 
The proportion of this group with neutrophilic inflammation is less certain because of variable 
cut-off points used to define neutrophilia. The higher the cut-off value used to define sputum 
neutrophilia the greater the proportion of subjects that are classified as having 
paucigranulocytic inflammation. Pathways that may account for poor asthma control in 
patients with non-eosinophilic asthma including neutrophilic inflammation, associated 
inflammatory phenotypes (Th1-high inflammation, Th17-high inflammation,  combination of  
Th2 and Th17 inflammation, mast cell induced inflammation, other inflammatory mechanisms) 
as well as  corticosteroid insensitivity. Non-inflammatory mechanisms such as  airway 
hyperreactivity and airway remodelling may be important in causing symptoms in some 
individuals. Potential treatments targeting specific pathways are listed in the diagram. Novel 
small molecules targeting neutrophilic inflammation, such as CXCR2 antagonists reduce 
neutrophils, but do not improve clinical outcomes. Smoking cessation in asthmatic smokers and 
removal from  exposure to occupational agents reduces neutrophilic inflammation. The results 
of clinical trials of biological agents targeting mediators associated with non-eosinophilic 
inflammation, such as IL-17 and TNF-α are disappointing. Preliminary studies of ‘off-label’ use 
of licensed drugs suggest that macrolides show efficacy in non-smokers with non-eosinophilic 
severe asthma and statins, low-dose theophylline and PPARγ agonists may benefit asthmatic 
smokers with non-eosinophilic inflammation and associate corticosteroid insensitivity. Inhaled 
PDE4 inhibitors, dual PDE3 and PDE4 inhibitors, p38MAPK inhibitors, tyrosine kinase inhibitors 
and PI3kinase inhibitors are under development and these compounds may be of benefit in 
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treating non-eosinophilic inflammation and corticosteroid insensitivity. Long-acting 
bronchodilators and/or bronchial thermoplasty are possible treatment options for symptomatic 
patients with paucigranulocytic inflammation in whom there is no evidence of activated 
inflammatory pathways or corticosteroid insensitivity that could be targeted by specific 
therapies. 
Abbreviations: CXCR: C-X-C chemokine receptor; FLAP: 5-lipoxygenase-activating protein; IL: 
interleukin; PDE: phosphodiesterase; PI3K: phosphoinositide 3-kinase; PPARγ: peroxisome 
proliferator-activated receptor-γ;  
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ABSTRACT 
 
Non-eosinophilic airway inflammation occurs in approximately 50% of patients with asthma. It 
is subdivided into neutrophilic or paucigranulocytic inflammation, although the proportion  of 
each subtype is uncertain because of variable cut-off points used to define neutrophilia. This 
article reviews the evidence for non-eosinophilic inflammation being as a target for therapy in 
asthma and assesses clinical trials of licensed drugs, novel small molecules and biologics agents 
in non-eosinophilic inflammation. Current symptoms, rate of exacerbations and decline in lung 
function are generally less in non-eosinophilic asthma than eosinophilic asthma. Non-
eosinophilic inflammation is associated with corticosteroid insensitivity. Neutrophil activation in 
the airways and systemic inflammation is reported in neutrophilic asthma. Neutrophilia in 
asthma may be due to corticosteroids, associated chronic pulmonary infection, altered airway 
microbiome and/or delay neutrophil apoptosis. The cause of poorly controlled non-eosinophilic 
asthma may differ between patients and involve several mechanism including neutrophilic 
inflammation, Th2-low or other subtypes of airway inflammation and/or corticosteroid 
insensitivity as well as non-inflammatory pathways such as airway hyperreactivity and 
remodelling. Smoking cessation in asthmatic smokers and removal from  exposure to 
occupational agents reduces neutrophilic inflammation. Preliminary studies of ‘off-label’ use of 
licensed drugs suggest that macrolides show efficacy in non-smokers with non-eosinophilic 
severe asthma and statins, low-dose theophylline and PPARγ agonists may benefit asthmatic 
smokers with non-eosinophilic inflammation. Novel small molecules targeting neutrophilic 
inflammation, such as CXCR2 antagonists reduce neutrophils, but do not improve clinical 
outcomes in studies to date. Inhaled PDE4 inhibitors, dual PDE3 and PDE4 inhibitors, p38MAPK 
inhibitors, tyrosine kinase inhibitors and PI3kinase inhibitors are under development and these 
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compounds may be of benefit in non-eosinophilic inflammation. The results of clinical trials of 
biological agents targeting mediators associated with non-eosinophilic inflammation, such as IL-
17 and TNF-α are disappointing. Greater understanding of the mechanisms of non-eosinophilic 
inflammation in asthma should lead to improved therapies. 
 
Word count: 299  
 
Key words: Airway inflammation; asthma; biological agents; biomarkers; cigarette smoking; 
corticosteroid insensitivity; eosinophils; neutrophils; small molecules.  
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INTRODUCTION 
 
Personalised medicine in asthma aims is to individualise treatment using non-invasive 
biomarkers that predict a beneficial response and/or that identify individuals who are at risk of 
adverse effects [Agustí et al., 2015]. Several airway inflammatory phenotypes are recognised 
that help identify a therapeutic response to specific treatments in asthma. For example, 
eosinophilic airway inflammation, which is usually identified on the basesd on the presence of 
sputum or blood eosinophilia, predicts patients with asthma that are likely to obtain a 
favourable therapeutic response to corticosteroids [Pavord et al., 1999, Little et al., 2000, 
Green et al., 2002, Bacci et al., 2006, Berry et al., 2007] and to monoclonal antibodies targeting 
interleukin (IL)-5 [Pavord et al., 2012, Katz et al., 2014, Thomson, 2014].   Type 2 helper T-cell 
(Th2)-high subtype of asthma is associated with increased epithelial expression of interleukin IL-
4, IL-5 and IL-13 [Woodruff et al., 2009, Arron et al., 2013] and is considered to overlap with 
eosinophilic airway inflammation [Arron et al., 2013]. Evidence from clinical trials suggests that 
the presence of Type-2 eosinophilic inflammation predicts a therapeutic response not only to 
corticosteroids [Woodruff et al., 2009], but to monoclonal antibodies targeting specific 
cytokines such as IL-5 [Bel et al., 2014, Ortega et al., 2014] and IL-13 [Corren et al., 2011]. Many 
patients with asthma have non-eosinophilic asthma, sometimes associated with neutrophilic 
inflammation and/or have a Th2-low type of inflammation. Compared to type-2 eosinophilic 
inflammation there are relatively few interventions available for non-type 2 inflammatory sub-
groups.  This article aims to discuss the evidence that non-eosinophilic airway inflammation, 
with or without neutrophic inflammation, is an appropriate target for therapy in asthma and 
also aims to assess the results of recent clinical trials of licensed drugs, novel small molecules 
and biologics agents in the treatment of non-eosinophilic asthma. 
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IS NON-EOSINOPHILIC AIRWAY INFLAMMATION AN APPROPRIATE TARGET FOR THERAPY IN 
ASTHMA? 
 
A number of factors need to be considered when attempting to answer the question of 
whether non-eosinophilic inflammation is an appropriate target for treatment in asthma  
including the criteria used to define neutrophilic and eosinophilic inflammation, the stability of 
non-eosinophil inflammation over time, the prevalence of non-eosinophilic inflammation, the 
strength of evidence for the involvement of non-eosinophilic inflammation in clinical features 
of asthma and the cause(s) of non-eosinophilic airway inflammation.  
 
Definition of eosinophilic and neutrophilic airway inflammation 
 
Non-eosinophilic airway inflammation is a term used to describe a subtype of asthma 
associated with normal numbers of sputum eosinophils. The non-eosinophilic phenotype is 
subdivided into neutrophilic inflammation, when neutrophil numbers are raised above a 
defined cut-off level or paucigranulocytic inflammation, when both eosinophil and neutrophil 
numbers are normal. In addition, some individuals have a mixed type of inflammation, when 
there is sputum neutrophilia and eosinophilia. Cut-off levels used to define sputum eosinophilia 
most commonly used are  >2% [Mcgrath et al., 2012, Hastie et al., 2013], >2%  [Peters et al., 
2014] or  >3% [Schleich et al., 2013, Zhang et al., 2014, Wagener et al., 2015]. A >3% cut-off is 
reported to be the most precise value to identify eosinophilic airway inflammation [Simpson et 
al., 2010]. Sputum eosinophil counts are associated with bronchial tissue eosinophil numbers 
suggesting that they provide a good indicator of airway eosinophilic pathology [Arron et al., 
2014].  The cut-off for a raised sputum neutrophil count is not clearly established with a wide 
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range of values reported in the literature: >40% (Nair, Gaga et al. 2012; Moore, Hastie et al. 
2014), >50% (Chaudhuri, Norris et al. 2014), >61% (Simpson, Milne et al. 2009), >65% (Nair et al 
2015) and >76% (Schleich, Manise et al. 2013). The most appropriate cut-off value that 
identifies individuals in whom neutrophils are activated and contributing to the pathogenic 
processes in asthma is not certain. In addition, sputum neutrophils do not correlate with 
bronchial tissue numbers bringing into doubt their predictive value for identifying neutrophil-
induced airway pathology [Arron et al., 2014].  In addition to the presence of non-eosinophilic 
inflammation, Haldar and Pavord [Haldar et al., 2007] proposed that the criteria for a diagnosis 
of non-eosinophilic asthma should include objective evidence of airflow obstruction or airway 
hyperreactivity, a raised asthma control questionnaire (ACQ) score (>1.5) and the absence of a 
significant smoking history, fixed airflow obstruction or associated bronchiectasis . In the 
current article, the criteria for non-eosinophilic asthma include the presence of non-
eosinophilic inflammation as defined above plus objective evidence of asthma,  but the review 
also includes data from patients with both normal and raised ACQ scores, who have a 
significant smoking history or who have fixed airflow obstruction. 
 
Stability of sputum cell counts 
  
Published data on the long term stability of sputum neutrophil and eosinophil counts is 
conflicting. Some studies report stable sputum cell counts in patients with mild to severe 
asthma follow-up over 6 months [Berry et al., 2007], 12 months [Green et al., 2002], 2 years 
[Jayaram et al., 2006] and 5 years [Simpson et al., 2006, Van Veen et al., 2009].  In contrast, 
sputum inflammatory cell phenotype changed in 48.6% of patients with severe asthma over 
1 year among patients recruited to the BIOmarkers in Severe Chronic AIRway Disease 
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(BIOAIR) study [Kupczyk et al., 2014]. Similar variability in sputum cell counts has been 
reported by others [Hancox et al., 2012]  and in one study a stable inflammatory  phenotype 
was found in only one third of patients [Al-Samri et al., 2010]. Transient sputum eosinophilia 
is reported in up to 40% patients with non-eosinophilic inflammation [Bacci et al., 2012, 
Mcgrath et al., 2012]. The potential for the lack of stability in non-eosinophilic inflammation 
over time needs to be accounted for in intervention studies targeting sputum inflammatory 
cell biomarkers. 
 
Prevalence of non-eosinophilic airway inflammation 
 
The different cut-off values used to define elevated sputum cell counts, particularly sputum 
neutrophils, may explain the variation in prevalence figures for non-eosinophilic 
inflammation between studies. Nevertheless, overall up to 50% of adults and adolescents 
patients with stable mild to severe asthma, and in some studies higher proportions, have 
non-eosinophilic inflammation [Gibson et al., 2001, Green et al., 2002, Simpson et al., 2006, 
Wang et al., 2011, Mcgrath et al., 2012, Schleich et al., 2013, Moore et al., 2014, Brooks et 
al., 2016 ]. For example, a review of sputum cytology data from 995 subjects with mild to 
moderate asthma enrolled in clinical trials undertaken by the Asthma Clinical Research 
Network (ACRN) reported that non-eosinophilic inflammation (sputum eosinophils <2%) was 
present in 64% of patients not taking inhaled corticosteroid and 83% of patients taking 
inhaled corticosteroids. In a sub-group of patients followed up for 6 months, 47% of the 
inhaled corticosteroid  free patients and 72% of those taking inhaled corticosteroids had 
persistent non-eosinophilic inflammation [Mcgrath et al., 2012]. In a cluster analysis 
performed on 423 patients recruited to the Severe Asthma Research Program  (SARP) 
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cohort, four asthma inflammatory sub-phenotypes were identified (sputum eosinophilia 
>2%; sputum neutrophilia >40%) [Moore et al., 2014]. Two groups had mild-to-moderate 
allergic asthma with minimal or eosinophil-predominant sputum inflammation whereas the 
other two sub-phenotypes had moderate-to-severe asthma with neutrophil-predominant or 
mixed granulocytic inflammation [Moore et al., 2014]. A study in a small group of adults 
with stable asthma found 51.7% of subjects had a paucigranulocytic phenotype, 27.6% 
neutrophilic inflammation and 17.2% eosinophilic inflammation [Wang et al., 2011].  
 
Involvement of neutrophilic and non-eosinophilic airway inflammation in asthma  
 
Evidence for the involvement of non-eosinophilic inflammation in asthma is based mainly on 
studies examining the association between sputum inflammatory phenotypes and clinical 
outcomes in asthma including current symptom control, exacerbations, airflow obstruction and 
therapeutic response to corticosteroids. Further evidence is provided by reports of local 
activation of neutrophils and systemic inflammation in neutrophilic asthma. 
 
Current symptom control 
 
The severity of current symptoms isare in general similar or slightly lowerbetter in non-
eosinophilic or neutrophilic subgroups of asthma compared to eosinophilic subgroups [Cowan 
et al., 2010, Hastie et al., 2010, Wood et al., 2012, Schleich et al., 2013, Baines et al., 2014, 
Newby et al., 2014, Schleich et al., 2014].   
 
Exacerbations 
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Sputum neutrophilia is found in up to 80% of exacerbations in adults with asthma [Turner et al., 
1995, Fahy et al., 1995 , Lamblin et al., 1998, Green et al., 2002, Jayaram et al., 2006, 
Maneechotesuwan et al., 2007, Wang et al., 2011], although the predominant sputum cell type 
can alter during successive exacerbations [D'silva et al., 2007]. Sputum eosinophilia is a better 
predictor of future exacerbations than sputum neutrophilia [Jatakanon et al., 2000, Leuppi et 
al., 2001, Kupczyk et al., 2014, Schleich et al., 2014]. For example, a cluster analysis performed 
on patients recruited to the BIOAIR study identified two clusters with raised sputum eosinophil 
counts that accounted for 83% of subjects who had 2 or more severe exacerbations during 
follow-up  for 1 year [Kupczyk et al., 2014]. One of these clusters had a mixed inflammatory 
profile with raised sputum neutrophils (43% percent of patients). A further cluster had a raised 
neutrophil count and a normal eosinophil count (11% of patients) and a non-eosinophilic 
paucigranulocytic inflammation was found in only 6% of cases. Patients with severe asthma 
associated with eosinophil inflammation have more intubations than non-eosinophilic patients 
[Wenzel et al., 1999]. 
 
Airflow obstruction 
  
Sputum neutrophilia is association with reduced lung function and based on this finding it has 
been speculated that airway neutrophils may contribute to the development of persistent 
airflow obstruction in asthma [Little et al., 2002, Shaw et al., 2007]. Against this hypothesis, a 
recent cluster analysis of lung function decline and sputum eosinophil count performed in 97 
patients with severe asthma identified a non-eosinophilic group in whom the decline in FEV1 
was -14 ml per year compared to an eosinophilic group with highly variable eosinophil counts 
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that had a greater rate of decline in FEV1 of -41 ml per year [Newby et al., 2014]. These findings 
suggest that eosinophilic inflammation, particularly when there is high variability in eosinophil 
count, is a greater risk factor for the development of persistent airflow obstruction than non-
eosinophilic inflammation.  Bronchodilator reversibility and airway hyperresponsiveness are 
similar in eosinophilic and non-eosinophilic asthma [Berry et al., 2007, Mcgrath et al., 2012], 
although one study noted greater airway hyperresponsiveness in persistent or intermittent 
eosinophilic groups [Mcgrath et al., 2012].  
 
Impaired response to inhaled corticosteroids  
 
Non-eosinophilic inflammation is associated with an impaired therapeutic response to 
inhaled corticosteroids [Pavord et al., 1999, Green et al., 2002, Bacci et al., 2006, Berry et 
al., 2007, Thomson et al., 2009, Mcgrath et al., 2012], although the lack of efficacy may not 
be complete. Several clinical studies performed in small numbers of patients with non-
eosinophilic asthma suggest that this group may obtain some benefit from inhaled 
corticosteroids although less than that found in eosinophilic patients [Godon et al., 2002, 
Cowan et al., 2010, Lemière et al., 2011]. Intermittent eosinophilia might be a factor 
accounting for corticosteroid sensitivity in some of these patients [Bacci et al., 2012, 
Mcgrath et al., 2012, Suárez-Cuartín et al., 2015]. 
 
Evidence for neutrophil activation in asthma 
 
There is evidence to suggest that the innate immune system is activated in chronic asthma. 
Firstly, sputum IL-8 and neutrophil elastase concentrations and innate immune receptors 
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TLR2, TLR4 and CD14 as well as pro-inflammatory IL-8 and IL1-β gene expression levels are 
increased in neutrophilic asthma compared to non-neutrophilic asthma [Simpson et al., 
2007, Wood et al., 2012]. Secondly, neutrophil activation, as measured by sputum 
myeloperoxidase (MPO) levels, is positively associated with sputum neutrophil numbers in 
asthma [Little et al., 2002]. Thirdly, specific sputum gene expression signatures are 
reported to discriminate eosinophilic asthma from non-eosinophilic asthma as well as to 
predict a beneficial response to inhaled corticosteroids [Baines et al., 2014]. In this study, 
non-eosinophilc asthma was identified by increased sputum cell expression of IL1β , 
alkaline phosphatase, tissuenonspecific isozyme (ALPL ) and CXCR2, whereas  eosinophilic 
asthma was characterised by increased expression of Charcot-Leydon crystal protein  or 
galectin-10 (CLC), carboxypeptidase A3 (CPA3) and deoxyribonuclease I-like 3 (DNASE1L3). 
The NLRP3 inflammasome is upregulated in neutrophilic asthma and may increase the 
production of IL-1β [Simpson et al., 2014, Kim et al., 2015]. Anti-inflammatory responses 
may be impaired in non-eosinophilic asthma based on reduced sputum galectin-3 
concentrations, which increases uptake of apoptotic neutrophils and reduced IL-1RA/IL-1ß 
ratio, and which might increase pro-inflammatory actions of IL-1ß [Gao et al., 2015]. In 
addition, soluble receptor for advanced glycation end-products (RAGE), which is a pattern-
recognition receptor is deficient in BAL samples in neutrophilic asthma [Sukkar et al., 
2012]. The T-cell granzyme B pathway, which is though to mediate apoptosis of epithelial 
cells, might be defective in non-eosinophilic asthma, based on the finding of a higher ratio 
of the expression of granzyme B to its inhibitor in T cells in this group compared to 
eosinophilic asthma [Simpson et al., 2014]. 
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Systemic inflammation is increased in patients with neutrophilic airway inflammation. The 
proportion of patients with elevated CRP, IL-6 and neutrophil elastase concentrations is higher 
in neutrophilic asthma compared to a non-neutrophic group [Baines et al., 2011, Wood et al., 
2012]. Neutrophilic inflammation is associated with increased α-defensin and neutrophil 
protease gene expression in blood  [Baines et al., 2011]. In non-eosinophilic asthma, blood 
neutrophils released significantly higher levels of IL-8 at rest [Baines et al., 2010].  In a small 
study, gene expression markers of  systemic inflammation were associated with higher BMI, 
greater history of cigarette smoking, lower FVC% predicted, and increased sputum neutrophils 
[Fu et al., 2013]. 
 
Potential inflammatory processes leading to non-eosinophilic airway inflammation 
 
Several inflammatory processes could lead to non-inflammation and airway damage in 
asthma although the exact immunological mechanisms are unclear (Figure 1) [Trejo Bittar 
et al., 2015]. Uncertainty in the clinical relevance of experimental animal models of non-
eosinophilic inflammation has hampered progress in understanding the involvement of 
neutrophils and non-eosinophilic inflammation in the pathogenesis of asthma. Stimuli such 
as viruses, cigarette smoke and pollutants could induce the release of chemoattractants 
including  IL-8 to recruit neutrophils to the airways. In experimental asthma models, the 
release of  IL-17A and IL-17F  from activated Th17 cells stimulates the synthesis of 
neutrophil chemoattractants including CXCL1 and IL-8 from the airway epithelium.  
[Newcomb et al., 2013].  INF-γ may also be involved in the pathogenesis of severe asthma 
associated with neutrophilic and eosinophilic inflammation, possibly in part through the 
release of IFN-γ from Th1 cells [Raundhal et al., 2015 ]. Data from patients with severe 
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asthma and an experimental murine asthma model implicate high INF-γ  immune 
responses and low secretory leukocyte protease inhibitor expression (SLPI) in airway 
epithelial cells with airway hyperrespponsiveness [Raundhal et al., 2015 ]. Neutrophils are a 
potential source of oxygen free radicals and enzymes and their ability to activate other 
airway cell types [Futosi et al., 2013]. Neutrophils in asthma are implicated in causing  
mucus gland hyperplasia and hypersecretion, airway hyperreactivity and remodelling as 
well as corticosteroid insensitivity. Interestingly, Th1 and Th17 cells may induce airway 
hyperreactivity and/or remodelling independently of neutrophil activation.   
 
Limited information has been published on the immunopathological characteristics of non-
eosinophilic inflammation in asthma compared with other inflammatory airway phenotypes 
including Th2-low inflammation, Th17-high inflammation or combination of Th2/Th17 profiles. 
Bronchial biopsy studies of patients with non-eosinophilic asthma and with Th2-low 
inflammation report reduced sub-mucosal eosinophil numbers and normal sub-epithelial 
basement membrane thickness in both groups [Wenzel et al., 1999, Berry et al., 2007, 
Woodruff et al., 2009]. In contrast, bronchial eosinophils numbers and sub-epithelial basement 
membrane thickness are both increased in eosinophilic asthma and in Th2-high asthma [Wenzel 
et al., 1999, Berry et al., 2007, Woodruff et al., 2009]. Mast cell numbers are increased in 
eosinophilic asthma [Wenzel et al., 1999] and Th2-high asthma [Dougherty et al., 2010], 
whereas mast cells numbers are normal in the sub-mucosal of patients with severe non-
eosinophilic asthma [Wenzel et al., 1999] and in the epithelium of non-smoker with Th2-low 
asthma [Dougherty et al., 2010].  Mast cell numbers in airway smooth muscle are increased in 
both non-eosinophilic and eosinophilic asthma  [Berry et al., 2007]. Bronchial biopsy neutrophil 
numbers are increased to a similar degree in non-eosinophilic severe asthma and eosinophilic 
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severe asthma [Wenzel et al., 1999]. Neutrophil numbers in Th2-low asthma have not been 
reported. A lower proportion of subjects with non-eosinophilic asthma are atopic compared to 
eosinophilic asthma (18% versus 66%) [Berry et al., 2007] and (58% versus 83%) [Gibson et al., 
2001]. Severe asthma associated with neutrophilia has significantly higher sputum levels of 
Th17-related cytokines (CXCL1, CXCL10 , CCL2, IL-6, and IL-8) compared with severe asthmatics 
with other inflammatory phenotypes [Manni et al., 2014]. The proportion of Th17 lymphocytes 
and the ratio of Th17 to regulatory T cells (Treg) in the peripheral blood is greater in patients 
with non-eosinophilic asthma taking inhaled corticosteroids compared to an eosinophilic 
asthma group [Furukawa et al., 2015]. Approximately one third of patients with severe 
eosinophilic asthma have a Th17-high signature that is associated with a Th2-low gene 
expression profile [Choy et al., 2015].  The number of subjects with non-eosinophilic severe 
asthma in this study was not sufficient to determine their Th17 profile [Choy et al., 2015]. 
Taken together, these finding suggest that non-eosinophilic inflammation and Th2-low 
inflammation in non-smokers with asthma share some similar immunopathological features 
including normal eosinophil numbers, submucosal mast cell numbers and sub-epithelial 
basement membrane thickness. There is a need for further studies to establish the similarities 
and differences in endotypes of non -eosinophilic, Th2-low and Th17 high inflammation to help 
identify sub-groups of patients for targeted therapies. 
 
 
Factors accounting for neutrophilic airway inflammation in asthma 
 
Several factors mechanisms either alone or in combination could explain raised sputum 
neutrophil counts in asthma (Table 1). Firstly, corticosteroids inhibit apoptosis of neutrophils 
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[Cox, 1995] and  their use in asthma may contribute to sputum neutrophilia [Saffar et al., 2011]. 
In addition, Th2-targeted therapies, including oral corticosteroids may contribute to the 
development of Th17-high neutrophilic inflammation [Choy et al., 2015, Shum, 2015].  In 
support of corticosteroids causing neutrophilia in asthma this suggestion, inhaled corticosteroid 
withdrawal from patients with moderate asthma resulted in only one subject with neutrophilic 
inflammation although the reintroduction of inhaled fluticasone for 4 weeks resulted in a raised 
neutrophil count in only 5% of subjects [Cowan et al., 2010]. In one study of patients with 
severe oral corticosteroid dependent asthma associated with increased sputum neutrophil 
number,  markers of neutrophil activation including oxidative burst and surface granular 
receptor expression were similar to patients with mild asthma [Nair et al., 2015]. In the SARP 
cohort, however corticosteroid use was not associated with sputum neutrophilia, suggesting 
that continuous corticosteroid exposure may not be the only influence on sputum neutrophil 
numbers in severe asthma [Moore et al., 2014].  Secondly, co-morbid conditions such 
bronchiectasis or severe airflow obstructions occurring in association with asthma may result in 
neutrophilic inflammation. Thirdly, delayed human neutrophil apoptosis has been reported in 
severe asthma [Uddin et al., 2010], possibly due to epithelial growth factor induced release of 
mediators with neutrophil chemotactic and anti-apoptotic actions from bronchial epithelial 
cells [Uddin et al., 2010, Uddin et al., 2013]. Fourthly, macrophage efferocytosis is impaired in 
non-eosinophilic asthma, which may cause airway neutrophilia [Simpson et al., 2013]. Fifthly, 
altered airway microbiome has been implicated in airway neutrophilia. Airway colonisation 
determined by terminal restriction fragment length polymorphism (T-RFLP) analysis is 
associated with more severe airways obstruction and longer duration of disease as well as 
neutrophilic airway inflammation and raised sputum IL-8 levels [Simpson et al., 2013, Green et 
al., 2014]. Taken together, these finding suggest that the cause of airway neutrophilia in 
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asthma is likely to be complex, possibly due to  corticosteroid treatment inducing  impaired 
apoptosis of neutrophils and Th17 mediated neutrophilic inflammation, delayed apoptosis of 
neutrophils due to epithelial growth factor release and ineffective macrophage efferocytosis of 
neutrophils  as well as an altered airway microbiome. 
 
Clinical phenotypes associated with non-eosinophilic inflammation  
 
Non-eosinophilic inflammation, either paucigranulocytic or neutrophilic occurs in a range of 
clinical phenotypes that account for approximately 50% of adults never or ex-smokers with mild 
to severe asthma or that have controlled or uncontrolled asthma (Table 2). Non-eosinophilic 
inflammation, with or without neutrophilic inflammation is commonly found in smokers with 
asthma [Chalmers et al., 2002, Boulet et al., 2006, Thomson et al., 2013]. A high BMI is 
associated with non-eosinophilic asthma in some people [Haldar et al., 2008], although others 
have submucosal eosinophilia [Desai et al., 2013] . Approximately two thirds of cases of 
occupational asthma due to low molecular weight agents have non-eosinophilic inflammation 
[Anees et al., 2002], which is associated with a poor asthma prognosis [Lemiere et al., 2014]. 
Non-occupational-induced asthma that is exacerbated by work exposures is associated with 
non-eosinophilic phenotype [Lemière et al., 2013].  Additional factors associated with higher 
neutrophil counts include older age [Brooks et al., 2013], exposure to environmental pollution 
through living close to car pollution [Wallace et al., 2011], exposure to occupational particulate 
matter [Simpson et al., 2015] and respiratory infections. 
 
Biomarkers that can identify non-eosinophilic airway inflammation 
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Are there biomarkers that can identify patients with non-eosinophilic airway inflammation? 
Blood eosinophil numbers are moderately associated with sputum eosinophils [Schleich et al., 
2013, Zhang et al., 2014, Wagener et al., 2015].  Using a cut-off for a blood eosinophil count of 
>0.22 x 10
9
/L 
3 
[Schleich et al., 2013], >0.26 x 10
9
/L [Zhang et al., 2014] or >0.27 x 10
9
/L 
[Wagener et al., 2015] accurately predicts sputum eosinophilia. In contrast, another study 
reported that blood eosinophils had a poor predictive value of 47% for sputum eosinophilia 
(>3% cut-off) although this was better in severe asthma (71%) [Hastie et al., 2013]. In patients 
with mild to severe asthma, blood eosinophils were reported to be better than serum periostin 
and exhaled nitric oxide in identifying sputum eosinophilia [Wagener et al., 2015]. Blood 
neutrophil numbers has a weak relationship with sputum neutrophil count [Schleich et al., 
2013, Zhang et al., 2014] and they have a poor predictive value for sputum neutrophilia (64% or 
38%  for a cut-off of >40% or >61% cut-off respectively) [Hastie et al., 2013]. In one study 
exhaled nitric oxide predicted inhaled corticosteroid response for airway hyperreactivity in non-
eosinophilic asthma (area under the curve 0.81), with an optimum cut-off point of 33 ppb 
[Cowan et al., 2010].  
 
Which inflammatory phenotype to target? 
 
In summary, non-eosinophilic airway inflammation is found in approximately 50% of patients 
with mild to severe asthma. The proportion of this group with neutrophilic inflammation is less 
certain because of variable cut-off points used in different studies to define neutrophilia. 
Current symptoms, rate of exacerbations and rate of decline in lung function are generally less 
severe in non-eosinophilic asthma compared to eosinophilic asthma. Non-eosinophilic 
inflammation is associated with an impaired response to inhaled corticosteroids. There is some 
Page 80 of 126
http://mc.manuscriptcentral.com/TAR
Therapeutic Advances in Respiratory Disease
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 Management of non-eosinophilic asthma  18 
 
evidence that neutrophils are activated in the airways of patients with neutrophilic asthma and 
that biomarkers of systemic inflammation is increased in this group. Neutrophilia in asthma 
may be due to corticosteroids, associated chronic pulmonary infection, altered airway 
microbiome and/or delay neutrophil apoptosis, particularly in severe disease. Non-eosinophilic 
asthma and Th2-low asthma may share some common immunopathological features, but 
further investigation is required. Due to the lack of effective specific therapies targeting non-
eosinophilic inflammation including neutrophilic inflammation there is currently no definitive 
evidence for the involvement of these inflammatory phenotypes in chronic asthma. Additional 
pathways may account for poor asthma control in patients with non-eosinophilic asthma 
including Th1 inflammation, Th17 inflammation, or a combination of  Th2 and Th17 
inflammation as well as  corticosteroid insensitivity (Figure 1). Recent work suggests a 
reciprocal relationship between Th2 and Th17 pathways in severe disease and that 
corticosteroid treatment may contribute to the emergence of a Th17-high profile [Choy et al., 
2015]. Non-inflammatory mechanisms may also be important in some individuals including 
airway hyperreactivity and airway remodelling.  
 
TREATMENTS TARGETING NON-EOSINOPHILIC AIRWAY INFLAMMATION 
 
Many patients with asthma continue to have poorly controlled disease despite treatment with 
currently available therapies. There is an unmet need for novel treatments that will impact 
favourably on clinical outcomes in patients with non-eosinophilic inflammation.  Non-
pharmacological interventions, ‘off-label’ use of licensed drugs, novel small molecules and 
biologics agents are being investigated as possible treatments of non-eosinophilic inflammation 
in asthma (Table 3 and Figure 2)..  
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Non-pharmacological interventions  
 
Avoidance from exposure to environmental and occupational pollutants may reduce 
neutrophilic inflammation in asthma. In a study of smokers with asthma of whom a 
subgroup quit smoking for 6 weeks the proportion of sputum neutrophils reduced, 
corticosteroid sensitivity improved  and the FEV1 increased compared to those who 
continued to smoke [Chaudhuri et al., 2006]. After cessation of exposure to occupational 
agents, neutrophilic inflammation reduced in people in whom their asthma was cured or 
improved compared to those in whom there was no improvement [Maghni et al., 2004].  
Several clinical trials have examined the effect of dietary supplement of vitamin D in asthma, 
based on the anti-inflammatory and corticosteroid-enhancing actions of vitamin D [Nanzer et al., 
2013, Zhang et al., 2014] [Xystrakis et al., 2006].  Two large randomized clinical trials of vitamin 
D3 supplementation in patients with asthma and vitamin D insufficiency [VIDA and ViDiAs trials), 
although not selected for specific airway inflammatory cell profiles or corticosteroid insensitivity, 
reported no improvements in clinical outcomes [Castro et al., 2014, Martineau et al., 2015, 
Denlinger et al., 2015 ]. Interestingly, vitamin D supplementation reduces eosinophilic 
inflammation in patients with non-atopic asthma, suggesting that certain inflammatory 
phenotypes might benefit from vitamin D3 supplementation [De Groot et al., 2015]. 
 
‘Off-label’ use of licensed drugs 
 
Several drugs licensed for the treatment of medical conditions other than asthma have been 
investigated for their efficacy in asthma, including patients with non-eosinophilic inflammation. 
Page 82 of 126
http://mc.manuscriptcentral.com/TAR
Therapeutic Advances in Respiratory Disease
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 Management of non-eosinophilic asthma  20 
 
Candidate drugs have been chosen usually because of pre-clinical evidence of anti-
inflammatory effects that might be relevant to treatment of asthma. Some examples are 
reviewed below. 
 
Macrolides 
 
Macrolides may be of benefit in the treatment of chronic asthma [Reiter et al., 2013], including 
non-eosinophilic asthma [Simpson et al., 2008], although prescribing macrolides as a long-term 
treatment increases the risk  of adverse drug effects and the development of microbial 
resistance [Cameron et al., 2012]. The mechanism(s) of action of macrolides in the treatment of 
airway diseases is not known, but could be due to antibacterial and/or anti-inflammatory 
actions, which include inhibition of NF-κB and other transcription factors as well as  reduction in 
neutrophil migration and/or function [Culic et al., 2001, Fujitani et al., 2003, Simpson et al., 
2008, Cameron et al., 2012, Kobayashi et al., 2013]. Macrolides have additional potentially 
beneficial properties including anti-viral actions [Gielen et al., 2010, Schögler et al., 2015] and 
an ability to restore corticosteroid sensitivity by inhibiting the phosphoinositide 3-kinase (PI3K) 
pathway and restoring histone deacetylase (HDAC)2 activity [Spahn et al., 2001, Charron et al., 
2007, Kobayashi et al., 2013, Hao et al., 2015] and by attenuating TNFα and IL-17 immune 
responses [Essilfie et al., 2015]. Two recent exploratory clinical trials have investigated the 
effects of macrolides in non-eosinophilic asthma. In one trial, smokers with mild to moderate 
asthma associated with non-eosinophilic inflammation were randomized to azithromycin 250 
mg per day or placebo [Cameron et al., 2013].  After 12 weeks, treatment with azithromycin 
was not associated with improvements in morning PEF, ACQ score, AQLQ score and 
methacholine PC20 compared to placebo and did not alter induced sputum differential counts, 
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bacterial load, C. pneumonia, M. pneumoniae seropositivity or upper airways respiratory virus 
prevalence. In an other randomized controlled trial patients with exacerbation-prone severe 
asthma received low-dose azithromycin or placebo as add-on treatment to combination 
therapy of inhaled corticosteroids and long-acting β2 agonists for 6 months [Brusselle et al., 
2013]. The rate of severe exacerbations and lower respiratory tract infections requiring 
treatment with antibiotics was not reduced by azithromycin. In a predefined subgroup with 
non-eosinophilic severe asthma (blood eosinophilia ≤200/µl) there was a reduction in the rate 
of primary endpoints in azithromycin-treated patients [Brusselle et al., 2013]. Azithromycin 
improved AQLQ scores, but did change ACQ scores or lung function. Based on these findings, 
further clinical trials of macrolides in non-eosinophilic severe asthma are indicated. Novel 
analogues of macrolides have been developed that have enhanced anti-inflammatory 
properties than current macrolides, such as solithromycin (CEM-101) [Kobayashi et al., 2013, 
Kobayashi et al., 2013] or that lack anti-bacterial properties, such as the non-antibiotic 
azithromycin derivative CSY0073 [Balloy et al., 2014].  
 
Statins 
 
Statins have pleiotropic immunomodulatory actions [Greenwood et al., 2006] that may of 
value in the treatment of chronic inflammatory diseases [Greenwood et al., 2006, Hothersall 
et al., 2006, Yeganeh et al., 2014]. In experimental models of allergic asthma [Mckay et al., 
2004, Zeki et al., 2009] and tobacco-smoke-induced lung inflammation [Lee et al., 2005, 
Davis et al., 2013] statins reduce inflammatory pathways potentially relevant to the 
pathogenesis of asthma and smoke-induced airway diseases. Statins might also restore 
corticosteroid sensitivity in asthma [Samson et al., 2006, Maneechotesuwan et al., 2010]. 
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Taken together, these findings suggest that statin treatment may have anti-inflammatory 
effects in people with asthma including smokers with asthma. A randomized double-blind 
parallel group trial undertaken in seventy one smokers with mild to moderate asthma 
associated with non-eosinophilic inflammation compared treatment with atorvastatin 40 mg 
per day with placebo. After 4 weeks treatment inhaled beclometasone 400 μg per day was 
added to both treatment arms for a further 4 weeks [Braganza et al., 2011]. At 4 weeks, 
there was an improvement in ACQ and AQLQ scores with atorvastatin, but not in lung 
function. There was no significant improvement with atorvastatin and inhaled 
beclometasone compared to inhaled beclometasone alone in clinical outcome measures at 
8 weeks. In a follow-up study the effects of atorvastatin alone and in combination with 
inhaled corticosteroid was investigated on their ability to suppress the concentration of a 
range of cytokines, chemokines and growth factors in sputum samples collected during the 
previous clinical trial [Braganza et al., 2011, Thomson et al., 2015 ].  Sputum mediator 
concentrations were not reduced by inhaled beclometasone alone. Atorvastatin significantly 
reduced sputum concentrations of CCL7, IL-12p70, sCD40L, FGF-2, CCL4, TGF-α and MMP-8 
compared with placebo and, when combined with inhaled beclometasone, reduced sputum 
concentrations of MMP-8, IL-1β, IL-10, MMP-9, sCD40L, FGF-2, IL-7, G-CSF and CCL7 
compared to ICS alone. Improvements in ACQ and/or AQLQ scores with atorvastatin and 
inhaled beclometasone were associated with decreases in G-CSF, IL-7, CCL2 and CXCL8. 
Interestingly, simvastatin suppresses airway IL-17 and upregulated IL-10 in patients with 
stable COPD [Maneechotesuwan et al., 2013]. Taken together, these findings suggest that 
short-term treatment with atorvastatin alone or in combination with inhaled 
beclometasone reduces several sputum cytokines, chemokines and growth factors 
concentrations unresponsive to inhaled corticosteroids alone in asthmatic smokers with 
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non-eosinophilic inflammation. There is a need for long-term clinical studies examining 
effect of statins on exacerbations and airway remodelling in chronic non-eosinophilic 
asthma. 
 
Low-dose theophylline 
 
Low dose theophylline has been shown to restore corticosteroid sensitivity in-vitro possibly 
by increasing HDAC-2 activity, which is suppressed in severe asthma and in smokers with 
asthma and a similar clinical effect might occur in people with severe disease or who are 
smokers [Barnes, 2009, To et al., 2010]. Theophylline inhibits oxidative stress dependent 
PI3K-δ activation and restores corticosteroid sensitivity in PBMCs from patients with COPD 
[To et al., 2010]. An exploratory clinical trial examined the effects of low dose theophylline 
added to inhaled  beclometasone compared to inhaled beclometasone alone in smokers 
with asthma associated with non-eosinophilic inflammation [Spears et al., 2009].   The 
addition of low dose theophylline to inhaled beclometasone, at a dose titrated to provide a 
‘sub-therapeutic’ concentration, resulted in increased efficacy as measured by lung function 
and suggested the restoration of corticosteroid sensitivity in those treated with the 
combination. Clinical trials to date have not investigated the therapeutic effects of adding 
low dose theophylline to patients with severe asthma. A fixed combination of ultra-low dose 
of theophylline with fluticasone, SKP-2075 (Skepharma), in a dry powder inhaler is under 
development for the treatment COPD. This combination would potentially be of benefit in 
the treatment of severe asthma and smokers with asthma, possibly in those people with 
non-eosinophilic inflammation. 
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PPARγ agonist 
 
In pre-clinical studies peroxisome proliferator-activated receptor-γ (PPARγ) agonists exert anti-
inflammatory effects potentially relevant to the treatment of inflammatory airway diseases 
including asthma and COPD [Spears et al., 2006, Belvisi et al., 2008, Seidel et al., 2012, Stephen 
et al., 2013, Bourke et al., 2014, Lakshmi et al., 2014, Lea et al., 2014, Donovan et al., 2015 ]. 
For example, PPARγ agonists reduce eosinophilic and neutrophilic lung infiltration in 
experimental animal models exposed to  allergen or tobacco smoke [Bauer et al., 2010, Lea et 
al., 2014, Zhao et al., 2014, Morissette et al., 2015]. The oral PPARγ agonist rosiglitazone had a 
modest effect in attenuating the allergen-induced late asthmatic response [Richards et al., 
2010]. A further proof of concept study reported that rosiglitazone compared with inhaled 
beclometasone dipropionate resulted in improvement in lung function and a borderline 
reduction in sputum IL-8 concentration in smokers with mild to moderate asthma that was 
associated with non-eosinophilic inflammation [Spears et al., 2009]. The oral PPARγ agonist 
pioglitazone is not effective in obese asthmatics [Dixon et al., 2015].  Inhaled PPARγ agonist 
analogues, such as AD3277 (Pulmagen) are under development for the treatment of chronic 
inflammatory airway diseases and potentially might be of benefit in non-eosinophilic asthma.  
 
Novel small molecule drugs  
 
Novel small molecule inhibitors have been developed for treating neutrophilic/non-eosinophilic 
asthma including CXCR2 antagonists, FLAP inhibitors, PDE4 inhibitors, dual PDE3 and PDE4 
inhibitor and various protein kinase inhibitors. 
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CXCR2 antagonist 
 
CXCR2 receptors are expressed on neutrophils as well as on airway goblet cells, fibroblasts 
and airway smooth muscle [Chapman et al., 2009]. Ligands for the CXCR2 receptor include 
the chemokines CXCL8 (IL-8), growth-related protein (Gro)-α, -β, and -γ (CXCL1–3), 
epithelial-derived neutrophil attractant-78 (ENA-78; CXCL5), granulocyte chemotactic 
protein-2 (GCP-2; CXCL6) and neutrophil- activating peptide-2 (NAP-2; CXCL7) [Chapman et 
al., 2009, Campbell et al., 2013]. Activation of  CXCR2 receptors result in neutrophil 
chemotaxis, proteases production, aairway goblet cell hyperplasia, pulmonary blood vessel 
angiogenesis, collagen deposition and airway smooth muscle contraction and  migration 
[Chapman et al., 2009]. The effects of CXCR2 antagonists have been studied on airway 
challenges that induce sputum neutrophilia. The CXCR2 antagonist, AZD8309 inhibits LPS-
induced airway neutrophilic inflammation in healthy volunteers [Leaker et al., 2013] and the 
CXCR2 antagonist, SB656933 inhibited ex vivo neutrophil activation and ozone-induced 
airway inflammation in humans [Lazaar et al., 2011]. The CXCR2 antagonist, SCH527123 
inhibits ozone-induced neutrophilia in healthy subjects [Holz et al., 2010]. A randomized, 
placebo-controlled clinical trial of the CXCR2 antagonist SCH527123 administered for 4 
weeks to patients with severe asthma and sputum neutrophils > 40% resulted in a reduction 
of 36.3% in sputum neutrophil percentage, fewer mild exacerbations and a trend towards 
improvement in ACQ score [Nair et al., 2012]. A clinical trial of the efficacy and safety of a 
CXCR2 antagonist AZD5069 in severe, uncontrolled persistent asthma reported that the 
addition of AZD5069 to combination ICS/LABA treatment did not improve clinical outcomes 
despite a dose-dependent reduction in blood neutrophil counts [O'byrne et al., 2015]. A lack 
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of improvement in clinical outcome despite a reduction in sputum neutrophil counts was 
reported with the CXCR2 antagonist AZD5069 in bronchiectasis [De Soyza et al., 2015]. A 
recent trial of the CXCR2 antagonist Navarixin (SCH527123) in COPD led to significant 
improvements in FEV1 and reduction in sputum neutrophil count, particularly in current 
smokers with COPD [Rennard et al., 2015].   The CXCR2 antagonist AZD8309 administered 
for 4 weeks to patients with moderate to severe COPD was well tolerated with no increase 
in the rate of infections [Kirsten et al., 2015]. A small-molecule oral CXCR2 antagonists 
Danirixin (GSK1325756) is undergoing a clinical trial in patients with COPD at risk of 
exacerbations (ClinicalTrials.gov Identifier: NCT02130193). Oral CXCR2 antagonists could 
potentially cause neutropenia, and the therapeutic index of these compounds requires 
careful assessment. 
 
FLAP inhibitors 
 
Pro-inflammatory cysteinyl leukotrienes (LTs) are synthesised from arachidonic acid in 
inflammatory cells by 5-lipoxygenase (LO) and 5-lipoxygenase activating protein (FLAP). 
FLAP inhibitors such as GSK-2190915 [Evans et al., 2008] prevent the formation of LTB4, 
which may be of value in  the treatment of neutrophilic asthma. GSK2190915 markedly 
inhibited ex vivo calcium ionophore stimulated blood LTB4 formation and urinary 
leukotriene E4 (LTE4) formation [Bain et al., 2013]. Pre-treatment with GSK2190915 reduces 
the early and late phase response to allergen challenge and results in a significant reduction 
of sputum LTB4 levels [Kent et al., 2013]. Despite suppressing the target mediator LTB4, the 
FLAP inhibitor GSK2190915 has no short-term effect on sputum cell counts or clinical 
endpoints in smokers and non-smokers with asthma associated with neutrophilic 
Page 89 of 126
http://mc.manuscriptcentral.com/TAR
Therapeutic Advances in Respiratory Disease
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 Management of non-eosinophilic asthma  27 
 
inflammation (sputum neutrophilia ≥ 50% for one sample and >45% for the other), 
suggesting that LTB4 suppression alone is inadequate in controlling airway neutrophils in 
asthma [Chaudhuri et al., 2014]. No active clinical trials of FLAP inhibitors in asthma are 
currently registered on ClinicalTrials.gov. 
 
PDE4 inhibitors and dual PDE3 and PDE4 inhibitors 
 
Phosphodiesterase (PDE)4 inhibitors have immunomodulatory effects on inflammatory cells 
potentially relevant to the treatment of asthma [Lipworth, 2005, Page et al., 2012, Kim et 
al., 2015 ]. In an allergen challenge study the oral PDE4 inhibitor roflumilast attenuated the 
rise in sputum eosinophils and neutrophils numbers after the late asthmatic response 
[Gauvreau et al., 2011]. High doses of PDE4 inhibitors may be necessary to treat severe 
asthma, and gastro-intestinal side effects limit their use [Lipworth, 2005, Bateman et al., 
2006, Bousquet et al., 2006]. The inhaled administration of PDE4 inhibitors may improve the 
therapeutic index of PDE4 inhibitors [Chapman et al., 2010, Singh et al., 2010, Nials et al., 
2011, De Savi et al., 2014, Moretto et al., 2015]. Inhaled PDE4 inhibitors GSK256066 and 
CHF6001 both inhibit allergen-induced late asthmatic responses [Singh et al., 2010, Dave et 
al., 2014] and in patients with moderate COPD  inhaled GSK256066 for 4 weeks was well 
tolerated although there was no inhibitory effect on sputum and blood inflammatory 
biomarkers [Watz et al., 2013]. The inhaled dual PDE3 and PDE4 inhibitor RPL554 (Verona 
Pharma) has bronchodilator effects and is well tolerated in patients with asthma and COPD 
[Franciosi et al., 2013]. In healthy subjects inhaled RPL554 attenuates the neutrophilic 
response to LPS challenge [Franciosi et al., 2013]. RPL554 is under development for the 
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treatment of asthma and COPD (ClinicalTrials.gov Identifier: NCT02427165 and 
NCT02542254 respectively). 
 
Protein kinase inhibitors 
 
Protein kinases are involved in cellular signalling of pro-inflammatory cytokines in asthma 
and the inhibition of these kinases may have a role in the treatment of severe asthma 
associated with non-eosinophilic asthma [Bhavsar et al., 2010, Cohen et al., 2010, 
Hammaker et al., 2010, Chung, 2011, Guntur et al., 2012].  Several p38MAPK inhibitors 
restore corticosteroid sensitivity in PBMCs from patients with severe asthma [Bhavsar et al., 
2010, Mercado et al., 2012] and COPD [Khorasani et al., 2015]. Clinical trials of  p38MAPK 
inhibitors oral losmapimod (GW856553) and inhaled AZD7624 are register for the treatment 
COPD (ClinicalTrials.gov Identifier: NCT02299375 and NCT02238483 respectively), although 
neither are registered for the treatment of asthma. Interestingly, a post-hoc analysis of a 6 
month clinical trial of oral losmapimod (GW856553) in COPD reported a reduction in 
exacerbations in a sub-group of patients with a blood eosinophil count <2% [Marks-
Konczalik et al., 2015], which may suggest a preferentially beneficial effect of p38MAPK 
inhibitors in non-eosinophilic inflammation. A imatinib, a specific ckit tyrosine kinase 
inhibitor that attenuates airway hyperresponsiveness, inflammation and remodelling in 
murine model of asthma [Berlin et al., 2005, Rhee et al., 2011] is under development for 
patients with severe refractory asthma (ClinicalTrials.gov Identifier: NCT01097694). A 
tyrosine kinase inhibitor masitinib targets c-kit and platelet-derived growth factor (PDGF) 
receptor improved asthma control in patients with severe corticosteroid-dependent asthma 
[Humbert et al., 2009] and a further clinical trial underway in patients with severe asthma 
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treated with oral corticosteroids (ClinicalTrials.gov Identifier:  NCT01449162). An alternative 
therapeutic strategy  to silencing c-kit with small interference RNA has been shown to  
attenuate inflammation in a murine model of allergic asthma [Wu et al., 2012, Wu et al., 
2014]. Clinical trials of protein kinase inhibitors have not been studied in patients with 
sputum inflammatory subtypes such as non-eosinophilic asthma. 
 
PI3kinase inhibitors 
 
Low dose theophylline is thought to act, at least in part, through the inhibition of PI3K [Ito et 
al., 2007, To et al., 2010]. Pre-clinical studies suggest that PI3K-δ inhibitors could potentially 
reverse corticosteroid insensitivity by increasing HDAC2 activity [Marwick et al., 2009, Marwick 
et al., 2010] and by reversing fungal-induced steroid resistant airway inflammation through 
modulation of endoplasmic reticulum stress [Lee et al., 2016]. Selective PI3K inhibitors are 
being developed as novel therapies for the treatment of chronic inflammatory airway diseases. 
An inhaled PI3Kδ inhibitor GSK2269557 is undergoing several clinical trials in asthma and COPD.  
PI3K δ and γ isoforms are involved in inflammatory cell recruitment and activation and dual 
PI3Kδ/γ inhibitors, such as TG100-115 and IPI-145 reduces airway inflammation induced by 
allergen or cigarette smoke in murine models [Doukas et al., 2009, Winkler et al., 2013] and 
restored corticosteroid sensitivity in the smoke model [Doukas et al., 2009]. RV1729,  a PI3Kδ/γ 
Inhibitor has undergone early stage clinical evaluation in asthma and COPD. SH2-containing 
inositol-50-phosphatase 1 (SHIP1) is an endogenous inhibitor of the PI3K pathway. A SPIP1 
activator AQX-1125 reduced the allergen-induced late asthmatic response with a non-
significant trend for a reduction in sputum eosinophils and neutrophils [Leaker et al., 2014]. 
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Further development of AQX-1125 is underway for the treatment of COPD (ClinicalTrials.gov 
Identifier: NCT01954628). 
 
Biological agents  
 
Monoclonal antibody blockers of inflammatory cytokines such as IL-17 and TNF-α that activate 
receptors on the surface of neutrophils have been investigated as treatments for asthma. 
 
IL-17 blockers 
 
In pre-clinical studies Th17 cells and IL-17 are implicated in causing neutrophilic inflammation 
and corticosteroid insensitivity [Shen et al., 2011, Newcomb et al., 2013, Chesné et al., 
2014]. IL-17 concentrations and expression are increased in BAL, sputum and bronchial 
biopsy samples in severe patients asthma that correlate with sputum neutrophils. 
Monoclonal inhibitors of IL-17 are in clinical development [Miossec et al., 2012]. 
Brodalumab is a human monoclonal antibody that binds with high affinity to human IL-
17RA, blocking the biologic activity of IL-17A, -17F, -17A/F heterodimer, and IL-25. A 
randomized clinical trial of  brodalumab in adults with inadequately controlled moderate to 
severe asthma receiving regular inhaled corticosteroids, but not selected for neutrophilic 
inflammation, reported no improvement in the primary outcome ACQ score or in  lung 
function and symptom-free days [Busse et al., 2013]. A subgroup with high bronchodilator 
reversibility demonstrated a borderline improvement an ACQ score. A further clinical trial of 
brodalumab in inadequately controlled asthma subjects with high bronchodilator 
reversibility was recently terminated due to a lack of observed efficacy in a pre-specified 
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interim analysis (ClinicalTrials.gov Identifier: NCT01902290). The results of a preliminary 
proof of efficacy study of the IL-17A monoclonal antibody blocker secukinumab (AIN457) in 
patients with uncontrolled asthma was also recently terminated. The investigators report 
that further investigations would require changes in study design, the use of different 
endpoints, a different IL-17 antibody or a different patient population (ClinicalTrials.gov 
Identifier: NCT01478360). 
 
TNF-α blockers 
 
Neutralizing TNFα restores corticosteroid sensitivity in a mouse model of neutrophilic airway 
inflammation [Dejager et al., 2015 ]. Several small clinical studies in severe asthma  of the 
soluble TNF-α receptor blocker etanercept reported beneficial effects on clinical outcomes 
[Howarth et al., 2005, Berry et al., 2006], whereas larger studies with etanercept [Holgate et al., 
2011] and the TNF-α receptor blocker golimumab [Wenzel et al., 2009] did not confirm a 
consistent beneficial clinical effect. When combined with concerns over increased risk of severe 
infections and malignancies with TNF-α receptor blocker treatment [Wenzel et al., 2009] it is 
unlikely that this target  will be developed further for the treatment of asthma. 
 
Other monoclonal antibodies 
  
Monoclonal antibodies that block IL-1β, for example, canakinumab or block the soluble IL-1 
receptor, for example, anakinra [Hernandez et al., 2015] might be of benefit in neutrophilic 
asthma, although no clinical studies are currently registered. An IL-6 monoclonal antibody 
blocker toclizumab is licensed for the treatment of rheumatoid arthritis. Toclizumab could 
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potentially be of benefit in neutrophilic asthma although no clinical studies are registered in 
asthma. 
 
Conclusions and future developments 
 
Non-eosinophilic airway inflammation is a term used to describe a subtype of asthma 
associated with normal numbers of sputum eosinophils. Up to 50% of patients with stable mild 
to severe never or ex-smokers with asthma have non-eosinophilic inflammation and this 
inflammatory phenotype is also found in smokers with asthma, some patient with a high BMI or 
occupational asthma. The non-eosinophilic phenotype is subdivided into neutrophilic 
inflammation, when neutrophil numbers are raised above a defined cut-off level or 
paucigranulocytic inflammation, when both eosinophil and neutrophil numbers are normal. The 
relative proportions  of each subtype is uncertain because of variable cut-off points used to 
define neutrophilia. The most appropriate value that indicates that neutrophils are activated 
and contributing to the pathogenic processes in asthma is not certain. The severity of current 
symptoms are in general similar or slightly better in non-eosinophilic or neutrophilic subgroups 
of asthma compare to eosinophilic subgroups. Sputum eosinophilia is a better predictor of 
future exacerbations and a greater risk factor for more rapid decline in lung function than 
sputum neutrophilia. Non-eosinophilic inflammation is associated with an impaired therapeutic 
response to inhaled corticosteroids. Neutrophilic inflammation is associated with activation of 
the innate immune system in asthma and systemic inflammation. Several mechanisms either 
alone or in combination could explain raised sputum neutrophil counts in asthma including 
corticosteroids, associated chronic sinopulmonary infection, delay human neutrophil apoptosis 
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due to epithelial growth factor, impaired macrophage phagocytosis and altered airway 
microbiome. Limited information has been published on the immunopathological 
characteristics of non-eosinophilic inflammation compared with other inflammatory airway 
phenotypes including Th2-low inflammation, Th17-high inflammation or combination of 
Th2/Th17 profiles in asthma. Taken together, the finding suggest that non-eosinophilic 
inflammation and Th2-low inflammation in non-smokers with asthma share some similar 
immunopathological features including normal eosinophil numbers, submucosal mast cell 
numbers and sub-epithelial basement membrane thickness. Blood neutrophil numbers are a 
poor predictive for sputum neutrophilia. Due to the lack of effective specific therapies targeting 
non-eosinophilic inflammation including neutrophilic inflammation there is currently no 
definitive evidence for the involvement of these inflammatory phenotypes in chronic asthma. 
Additional pathways may account for poor asthma control in patients with non-eosinophilic 
asthma including Th1 inflammation, Th17 inflammation, or a combination of  Th2 and Th17 
inflammation as well as  corticosteroid insensitivity (Figure 2). The role of corticosteroid 
treatment in causing neutrophilic and Th17 inflammation in severe asthma requires further 
investigation. Non-inflammatory mechanisms may also be important in some individuals 
including airway hyperreactivity and airway remodelling.  
 
There is an unmet need for novel treatments that will impact favourably on clinical outcomes in 
patients with non-eosinophilic inflammation.  Non-pharmacological interventions, ‘off-label’ 
use of licensed drugs, novel small molecules and biologics agents are being investigated as 
possible treatments of non-eosinophilic inflammation in asthma. Smoking cessation in smokers 
with asthma and cessation of exposure to occupational agents are associated with a reduction 
in neutrophilic inflammation. Preliminary data of studies of ‘off-label’ use of licensed drugs 
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suggest that macrolides show efficacy in non-smokers with non-eosinophilic asthma and 
statins, low-dose theophylline and PPARγ agonist may be beneficial in asthmatic smokers with 
non-eosinophilic inflammation and corticosteroid insensitivity. Further clinical studies are 
indicated to confirm these findings and to determine the role of these therapies in the 
management of severe asthma. Novel small molecules targeting neutrophilic inflammation in 
asthma such as CXCR2 antagonists reduce neutrophil counts, but do not improve clinical 
outcomes. A FLAP inhibitor did not reduce neutrophils or improve symptoms. Inhaled PDE4 
inhibitors and dual PDE3 and PDE4 inhibitors are potential therapies for neutrophilic asthma 
and a dual PDE3 and PDE4 inhibitors is under development for the treatment of asthma and 
COPD. Additional small molecule drugs including p38MAPK inhibitors, tyrosine kinase inhibitors 
and PI3kinase inhibitors are under development for asthma. The development of biological 
agents to target non-eosinophilic inflammation in asthma has been disappointing to date with 
the termination of clinical programmes of monoclonal antibodies targeting IL-17 and TNF-α. In 
the future, the selection of patients with severe asthma and evidence of Th17-high 
inflammation may be more likely to identify a subpopulation that respond to to IL-17 blockers.  
Long-acting bronchodilators and/or bronchial thermoplasty are possible treatment options for 
symptomatic patients with paucigranulocytic inflammation in whom there is no evidence of 
activated inflammatory pathways or corticosteroid insensitivity that could be targeted by 
specific therapies. 
 
Greater understanding of the mechanisms of non-eosinophilic inflammation in asthma should 
lead to improved therapies. International collaborative programmes of research investigating 
pathogenic mechanism of severe asthma have focused mainly on type 2 eosinophilic 
inflammation. The Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-
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BOPRED) study [Shaw et al., 2015 ] and the UK Refractory Asthma Stratification Programme 
(RASP-UK) [Heaney et al., 2015 ] are designed to identify new phenotypes/endotypes and 
treatment targets and will hopefully identify new approaches to the treatment of patients with 
non-eosinophilic asthma. 
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LIST OF ABBREVIATIONS 
 
ACQ: Asthma control questionnaire 
ACRN: Asthma Clinical Research Network  
AP-1: Activator protein-1  
AQLQ: asthma quality of life questionnaire 
BAL: Bronchoalveolar lavage  
BDP: Beclomethasone dipropionate  
BMI: Body mass index 
CAMP: Childhood Asthma Management Program  
COPD: Chronic obstructive pulmonary disease 
CRHR1: Corticotrophin-releasing hormone receptor 1 gene  
CCL: Chemokine (C-C motif) ligand 
CXCL: Chemokine (C-X-C motif) ligand 
CXCR: C-X-C chemokine receptor 
eNOS: Endothelial nitric oxide synthase  
ERK: Extracellular signal-regulated kinase  
FCER2: Low-affinity IgE receptor gene  
Page 116 of 126
http://mc.manuscriptcentral.com/TAR
Therapeutic Advances in Respiratory Disease
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 Management of non-eosinophilic asthma  54 
 
FGF: Fibroblast growth factor 
FLAP: 5-lipoxygenase-activating protein  
GILZ: Glucocorticoid-inducible leucine zipper 1  
G-CSF: Granulocyte-colony stimulating factor 
GLCCI1: Glucocorticoid-induced transcript 1 gene  
GOAL: Gaining Optimal Asthma Control  
GR: glucocorticoid receptor  
GRE: Glucocorticoid-responsive elements  
HDAC: Histone deacetylase  
HFA: Hydrofluoroalkane  
HMG CoA: 3-Hydroxymethyl-3-glutaryl Coenzyme A  
IDO: Indoleamine 2, 3-dioxygenase  
IFN: interferon  
Ig: immunoglobulin  
IKKs: IκB kinases 
IL: interleukin 
JNK: c-Jun N-terminal kinase  
LABA: Long acting β2-agonists 
LPS: lipopolysaccharide  
LT: leukotriene 
MAPK: Mitogen-activated protein kinase  
MKP: Mitogen-activated protein kinase phosphatase 1 
MMP: Matrix metalloproteinase 
MPO: Myeloperoxidase 
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NO: nitric oxide  
NFκB: Nuclear factor κB  
PEF: Peak expiratory flow  
PBMC: Peripheral blood mononuclear cell  
PDE: Phosphodiesterase  
PI3K: Phosphoinositide 3-kinase  
PP2A: Protein phosphatase 2A  
PPARγ: Peroxisome proliferator-activated receptor-γ  
RASP-UK: Refractory Asthma Stratification Programme  
RBM: Reticular basement membrane thickness 
sCD40L: Soluble CD40 ligand 
SHIP1: SH2-containing inositol-50-phosphatase 1 
SLPI: Secretory leukocyte protease inhibitor expression    
SNPs: Single-nucleotide polymorphisms 
STAT: Signal transduction-activated transcription factors  
SNP: Single nucleotide polymorphisms 
TBX21: T-box expressed in T cells21  
TGF-α: Transforming growth factor alpha 
Th2: Type 2 helper T-cell (Th2) 
TNF-α: Ttumour necrosis factor α 
TLR: Toll-like receptor  
U-BOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome  
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Table 1 Possible factors accounting for cause(s) of neutrophilic airway inflammation in 
asthma 
 
• Corticosteroid treatment causing reduced apoptosis of neutrophils and contributing 
to Th17 mediated neutrophilic inflammation 
• Neutrophila associated with chronic sinopulmonary infection and/or bronchiectasis 
• Delay human neutrophil apoptosis in severe asthma due to epithelial growth factor 
induced release of mediators with neutrophil chemotactic and anti-apoptotic actions 
from bronchial epithelial cells 
• Impaired macrophage phagocytosis of neutrophils 
• Neutophilia associated with altered airway microbiome  
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Table 2 Clinical phenotypes and factors associated with non-eosinophilic airway 
inflammation in asthma 
 
Mild to severe asthma in never or ex-smokers (both controlled and uncontrolled) 
Smokers with asthma 
High BMI (subgroup) 
Occupational asthma (subgroup) 
Factors associated with higher neutrophil counts 
− Older age  
− Exposure to environmental pollution 
− Respiratory infections 
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 Table 3 Treatments targeting non-eosinophilic airway inflammation in asthma 
 
Non-pharmacological interventions  
 
Avoidance from exposure to environmental and occupational pollutants 
Smoking cessation  
Dietary supplementation with vitamin D3 
 
 
‘Off-label’ use of licensed drugs 
 
Macrolides 
Statins 
Low-dose theophylline 
Peroxisome proliferator-activated receptor-γ (PPARγ) agonists  
 
Novel small molecule drugs 
 
Drugs targeting neutrophilic inflammation 
C-X-C chemokine receptor (CXCR)2 antagonists  
5-lipoxygenase-activating protein (FLAP) inhibitors 
 
Phosphodiesterase (PDE) inhibitors  
PDE4 inhibitors  
Dual PDE3 and PDE4 inhibitors  
Page 121 of 126
http://mc.manuscriptcentral.com/TAR
Therapeutic Advances in Respiratory Disease
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 Management of non-eosinophilic asthma  59 
 
Protein kinase inhibitors 
p38 Mitogen-activated protein kinase (MAPK) inhibitors 
Narrow spectrum kinase inhibitors 
Tyrosine kinase inhibitors  
 
Phosphoinositide 3 (PI3)-kinase inhibitors 
PI3K-δ inhibitors  
Dual PI3Kδ/γ inhibitors 
 
Biological agents 
 
Interleukin (IL)-17A receptor blockers 
IL-17A blockers 
Tumour necrosis factor (TNF)-α receptor blockers 
IL-1β monoclonal antibody blockers 
Soluble IL-1 receptor monoclonal antibody blockers 
IL-6 monoclonal antibody blockers 
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FIGURE LEGENDS  
 
Figure 1 Schematic diagram of potential pathways leading to non-eosinophilic   
inflammation and airway damage in severe asthma 
 
Several inflammatory pathways could potentially lead to non-eosinophilic inflammation and 
airway damage in asthma although the exact mechanisms are unclear. Possible pathways 
are briefly summarized in the schematic diagram. Stimuli such as viruses, cigarette smoke 
and pollutants could induce the release of chemoattractants including IL-8 to recruit 
neutrophils to the airways. The release of IL-17A and IL-17F from activated Th17 cells could 
stimulate the synthesis of neutrophil chemoattractants, such CXCL1 and IL-8 from the 
airway epithelium.  INF-γ may also be involved in non-eosinophilic asthma, possibly in part 
through its release from Th1 cells. Inflammatory mediators released by neutrophils are 
implicated in causing  mucus gland hyperplasia and hypersecretion, airway hyperreactivity 
and remodelling as well as corticosteroid insensitivity in asthma. Th1 and Th17 cells may 
induce airway hyperreactivity and/or remodelling independently of neutrophil activation.   
Abbreviations: CXCL1: chemokine (C-X-C motif) ligand; IFN: interferon; IL: interleukin; LT: 
leukotriene; MMP: matrix metalloproteinase; MPO: myeloperoxidase; ROC: reactive oxygen 
species; TNF-α: tumour necrosis factor α 
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Figure 21 Targets and potential therapies for treating non-eosinophilic airway 
inflammation in asthma 
 
Non-eosinophilic airway inflammation is found in approximately 50% of patients with asthma. 
The proportion of this group with neutrophilic inflammation is less certain because of variable 
cut-off points used to define neutrophilia. The higher the cut-off value used to define sputum 
neutrophilia the greater the proportion of subjects that are classified as having 
paucigranulocytic inflammation. Pathways that may account for poor asthma control in 
patients with non-eosinophilic asthma including neutrophilic inflammation, associated 
inflammatory phenotypes (Th1-high inflammation, Th17-high inflammation,  combination of  
Th2 and Th17 inflammation, mast cell induced inflammation, other inflammatory mechanisms) 
as well as  corticosteroid insensitivity. Non-inflammatory mechanisms such as  airway 
hyperreactivity and airway remodelling may be important in causing symptoms in some 
individuals.  
Potential treatments targeting specific pathways are listed in the diagram. Novel small 
molecules targeting neutrophilic inflammation, such as CXCR2 antagonists reduce neutrophils, 
but do not improve clinical outcomes. Smoking cessation in asthmatic smokers and removal 
from  exposure to occupational agents reduces neutrophilic inflammation. The results of clinical 
trials of biological agents targeting mediators associated with non-eosinophilic inflammation, 
such as IL-17 and TNF-α are disappointing. Preliminary studies of ‘off-label’ use of licensed 
drugs suggest that macrolides show efficacy in non-smokers with non-eosinophilic severe 
asthma and statins, low-dose theophylline and PPARγ agonists may benefit asthmatic smokers 
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with non-eosinophilic inflammation and associate corticosteroid insensitivity. Inhaled PDE4 
inhibitors, dual PDE3 and PDE4 inhibitors, p38MAPK inhibitors, tyrosine kinase inhibitors and 
PI3kinase inhibitors are under development and these compounds may be of benefit in treating 
non-eosinophilic inflammation and corticosteroid insensitivity. Long-acting bronchodilators 
and/or bronchial thermoplasty are possible treatment options for symptomatic patients with 
paucigranulocytic inflammation in whom there is no evidence of activated inflammatory 
pathways or corticosteroid insensitivity that could be targeted by specific therapies. 
Abbreviations: CXCR: C-X-C chemokine receptor; FLAP: 5-lipoxygenase-activating protein; IL: 
interleukin; PDE: phosphodiesterase; PI3K: phosphoinositide 3-kinase; PPARγ: peroxisome 
proliferator-activated receptor-γ;  
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Figure 1 Schematic diagram of potential pathways leading to non-eosinophilic   inflammation and airway 
damage in severe asthma  
 
Several inflammatory pathways could potentially lead to non-eosinophilic inflammation and airway damage 
in asthma although the exact mechanisms are unclear. Possible pathways are briefly summarized in the 
schematic diagram. Stimuli such as viruses, cigarette smoke and pollutants could induce the release of 
chemoattractants including IL-8 to recruit neutrophils to the airways. The release of IL-17A and IL-17F from 
activated Th17 cells could stimulate the synthesis of neutrophil chemoattractants, such CXCL1 and IL-8 from 
the airway epithelium.  INF-γ may also be involved in non-eosinophilic asthma, possibly in part through its 
release from Th1 cells. Inflammatory mediators released by neutrophils are implicated in causing  mucus 
gland hyperplasia and hypersecretion, airway hyperreactivity and remodelling as well as corticosteroid 
insensitivity in asthma. Th1 and Th17 cells may induce airway hyperreactivity and/or remodelling 
independently of neutrophil activation.    
Abbreviations: CXCL1: chemokine (C-X-C motif) ligand; IFN: interferon; IL: interleukin; LT: leukotriene; 
MMP: matrix metalloproteinase; MPO: myeloperoxidase; ROC: reactive oxygen species; TNF-α: tumour 
necrosis factor α  
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Figure 2 Targets and potential therapies for treating non-eosinophilic airway inflammation in asthma  
 
Non-eosinophilic airway inflammation is found in approximately 50% of patients with asthma. The 
proportion of this group with neutrophilic inflammation is less certain because of variable cut-off points used 
to define neutrophilia. The higher the cut-off value used to define sputum neutrophilia the greater the 
proportion of subjects that are classified as having paucigranulocytic inflammation. Pathways that may 
account for poor asthma control in patients with non-eosinophilic asthma including neutrophilic 
inflammation, associated inflammatory phenotypes (Th1-high inflammation, Th17-high 
inflammation,  combination of  Th2 and Th17 inflammation, mast cell induced inflammation, other 
inflammatory mechanisms) as well as  corticosteroid insensitivity. Non-inflammatory mechanisms such 
as  airway hyperreactivity and airway remodelling may be important in causing symptoms in some 
individuals. Potential treatments targeting specific pathways are listed in the diagram. Novel small molecules 
targeting neutrophilic inflammation, such as CXCR2 antagonists reduce neutrophils, but do not improve 
clinical outcomes. Smoking cessation in asthmatic smokers and removal from  exposure to occupational 
agents reduces neutrophilic inflammation. The results of clinical trials of biological agents targeting 
mediators associated with non-eosinophilic inflammation, such as IL-17 and TNF-α are disappointing. 
Preliminary studies of ‘off-label’ use of licensed drugs suggest that macrolides show efficacy in non-smokers 
with non-eosinophilic severe asthma and statins, low-dose theophylline and PPARγ agonists may benefit 
asthmatic smokers with non-eosinophilic inflammation and associate corticosteroid insensitivity. Inhaled 
PDE4 inhibitors, dual PDE3 and PDE4 inhibitors, p38MAPK inhibitors, tyrosine kinase inhibitors and PI3kinase 
inhibitors are under development and these compounds may be of benefit in treating non-eosinophilic 
inflammation and corticosteroid insensitivity. Long-acting bronchodilators and/or bronchial thermoplasty are 
possible treatment options for symptomatic patients with paucigranulocytic inflammation in whom there is 
no evidence of activated inflammatory pathways or corticosteroid insensitivity that could be targeted by 
specific therapies.  
Abbreviations: CXCR: C-X-C chemokine receptor; FLAP: 5-lipoxygenase-activating protein; IL: interleukin; 
PDE: phosphodiesterase; PI3K: phosphoinositide 3-kinase; PPARγ: peroxisome proliferator-activated 
receptor-γ;  
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